BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;2:999-1017. [PMID: 14654798 DOI: 10.1038/nrd1255] [Cited by in Crossref: 379] [Cited by in F6Publishing: 345] [Article Influence: 22.3] [Reference Citation Analysis]
Number Citing Articles
1 Berbari NF, Lewis JS, Bishop GA, Askwith CC, Mykytyn K. Bardet-Biedl syndrome proteins are required for the localization of G protein-coupled receptors to primary cilia. Proc Natl Acad Sci U S A 2008;105:4242-6. [PMID: 18334641 DOI: 10.1073/pnas.0711027105] [Cited by in Crossref: 332] [Cited by in F6Publishing: 306] [Article Influence: 25.5] [Reference Citation Analysis]
2 Khan M, Huang T, Lin CY, Wu J, Fan BM, Bian ZX. Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy. Oncotarget 2017;8:104615-37. [PMID: 29262666 DOI: 10.18632/oncotarget.18403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 Pasternak A, Feng Z, de Jesus R, Ye Z, He S, Dobbelaar P, Bradley SA, Chicchi GG, Tsao KL, Trusca D, Eiermann GJ, Li C, Feng Y, Wu M, Shao Q, Zhang BB, Nargund R, Mills SG, Howard AD, Yang L, Zhou YP. Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist. ACS Med Chem Lett 2012;3:289-93. [PMID: 24900466 DOI: 10.1021/ml200272z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
4 Schmid HA, Lambertini C, van Vugt HH, Barzaghi-Rinaudo P, Schäfer J, Hillenbrand R, Sailer AW, Kaufmann M, Nuciforo P. Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors. Neuroendocrinology. 2012;95:232-247. [PMID: 22156600 DOI: 10.1159/000330616] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
5 Sreenivasan VK, Kim EJ, Goodchild AK, Connor M, Zvyagin AV. Targeting somatostatin receptors using in situ- bioconjugated fluorescent nanoparticles. Nanomedicine 2012;7:1551-60. [DOI: 10.2217/nnm.12.42] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
6 Csaba Z, Peineau S, Dournaud P. Molecular mechanisms of somatostatin receptor trafficking. J Mol Endocrinol 2012;48:R1-12. [PMID: 22159161 DOI: 10.1530/JME-11-0121] [Cited by in Crossref: 36] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
7 Tatsi A, Maina T, Cescato R, Waser B, Krenning EP, de Jong M, Cordopatis P, Reubi JC, Nock BA. [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study. EJNMMI Res 2012;2:25. [PMID: 22682002 DOI: 10.1186/2191-219X-2-25] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
8 Seebach D, Widmer H, Capone S, Ernst R, Bremi T, Kieltsch I, Togni A, Monna D, Langenegger D, Hoyer D. NMR-Solution Structures and Affinities for the Human Somatostatin G-Protein-Coupled Receptors hsst1–5 of CF3 Derivatives of Sandostatin® (Octreotide). HCA 2009;92:2577-86. [DOI: 10.1002/hlca.200900279] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
9 Yeung M, Engin E, Treit D. Anxiolytic-like effects of somatostatin isoforms SST 14 and SST 28 in two animal models (Rattus norvegicus) after intra-amygdalar and intra-septal microinfusions. Psychopharmacology (Berl) 2011;216:557-67. [PMID: 21424237 DOI: 10.1007/s00213-011-2248-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
10 Sibille E, Morris HM, Kota RS, Lewis DA. GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders. Int J Neuropsychopharmacol. 2011;14:721-734. [PMID: 21226980 DOI: 10.1017/s1461145710001616] [Cited by in Crossref: 129] [Cited by in F6Publishing: 101] [Article Influence: 12.9] [Reference Citation Analysis]
11 Guo Y, Yao FR, Cao DY, Pickar JG, Zhang Q, Wang HS, Zhao Y. Somatostatin inhibits activation of dorsal cutaneous primary afferents induced by antidromic stimulation of primary afferents from an adjacent thoracic segment in the rat. Brain Res 2008;1229:61-71. [PMID: 18640104 DOI: 10.1016/j.brainres.2008.06.111] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
12 Foister S, Taylor LL, Feng J, Chen W, Lin A, Cheng F, Smith AB, Hirschmann R. Design and Synthesis of Potent Cystine-Free Cyclic Hexapeptide Agonists at the Human Urotensin Receptor. Org Lett 2006;8:1799-802. [DOI: 10.1021/ol060278h] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
13 Ben-Shlomo A, Pichurin O, Barshop NJ, Wawrowsky KA, Taylor J, Culler MD, Chesnokova V, Liu NA, Melmed S. Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. Mol Endocrinol 2007;21:2565-78. [PMID: 17609435 DOI: 10.1210/me.2007-0081] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
14 Ye DZ, Kaestner KH. Foxa1 and Foxa2 control the differentiation of goblet and enteroendocrine L- and D-cells in mice. Gastroenterology 2009;137:2052-62. [PMID: 19737569 DOI: 10.1053/j.gastro.2009.08.059] [Cited by in Crossref: 99] [Cited by in F6Publishing: 90] [Article Influence: 8.3] [Reference Citation Analysis]
15 Wei N, Liu R, Ou Y, Li X, Qiang O, Guo W, Tang CW. Effects of octreotide on glucose transporter type 2 expression in obese rat small intestine. World J Gastroenterol 2011; 17(39): 4434-4439 [PMID: 22110271 DOI: 10.3748/wjg.v17.i39.4434] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
16 Nilsson A, Stroth N, Zhang X, Qi H, Fälth M, Sköld K, Hoyer D, Andrén PE, Svenningsson P. Neuropeptidomics of mouse hypothalamus after imipramine treatment reveal somatostatin as a potential mediator of antidepressant effects. Neuropharmacology 2012;62:347-57. [PMID: 21856315 DOI: 10.1016/j.neuropharm.2011.08.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
17 Delgado M, Ganea D. Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents. Brain Behav Immun 2008;22:1146-51. [PMID: 18598752 DOI: 10.1016/j.bbi.2008.06.001] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 6.0] [Reference Citation Analysis]
18 Mothes C, Caumes C, Guez A, Boullet H, Gendrineau T, Darses S, Delsuc N, Moumné R, Oswald B, Lequin O, Karoyan P. 3-Substituted prolines: from synthesis to structural applications, from peptides to foldamers. Molecules 2013;18:2307-27. [PMID: 23429346 DOI: 10.3390/molecules18022307] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
19 Shenoy PA, Kuo A, Khan N, Gorham L, Nicholson JR, Corradini L, Vetter I, Smith MT. The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain. Front Pharmacol 2018;9:495. [PMID: 29867498 DOI: 10.3389/fphar.2018.00495] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
20 Pelay-gimeno M, Glas A, Koch O, Grossmann TN. Strukturbasierte Entwicklung von Protein-Protein-Interaktionsinhibitoren: Stabilisierung und Nachahmung von Peptidliganden. Angew Chem 2015;127:9022-54. [DOI: 10.1002/ange.201412070] [Cited by in Crossref: 76] [Cited by in F6Publishing: 41] [Article Influence: 12.7] [Reference Citation Analysis]
21 Staykova ST, Wesselinova DW, Vezenkov LT, Naydenova ED. Synthesis and in vitro antitumor activity of new octapeptide analogs of somatostatin containing unnatural amino acids. Amino Acids 2015;47:1007-13. [DOI: 10.1007/s00726-015-1929-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
22 der Hoek JV, Lamberts SWJ, Hofland LJ. The Role of Somatostatin Analogs in Cushing's Disease. Pituitary 2004;7:257-64. [DOI: 10.1007/s11102-005-1404-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
23 Loos JA, Negro P, Cumino AC. In vitro anti-echinococcal activity of octreotide: Additive effect of metformin linked to autophagy. Acta Trop 2020;203:105312. [PMID: 31870710 DOI: 10.1016/j.actatropica.2019.105312] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Domvri K, Bougiouklis D, Zarogoulidis P, Porpodis K, Xristoforidis M, Liaka A, Eleutheriadou E, Lampaki S, Lazaridis G, Organtzis J, Kyriazis G, Hohenforst-Schmidt W, Tsirgogianni K, Karavasilis V, Baka S, Darwiche K, Freitag L, Trakada G, Zarogoulidis K. Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC? J Cancer 2015;6:360-6. [PMID: 25767606 DOI: 10.7150/jca.11308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
25 Barragán F, Moreno V, Marchán V. Solid-phase synthesis and DNA binding studies of dichloroplatinum(ii) conjugates of dicarba analogues of octreotide as new anticancer drugs. Chem Commun (Camb) 2009;:4705-7. [PMID: 19641816 DOI: 10.1039/b909698a] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
26 Jin QJ, Sun JJ, Fang XT, Zhang CL, Yang L, Chen DX, Shi XY, Du Y, Lan XY, Chen H. Molecular characterization and polymorphisms of the caprine Somatostatin (SST) and SST Receptor 1 (SSTR1) genes that are linked with growth traits. Mol Biol Rep 2011;38:3129-35. [DOI: 10.1007/s11033-010-9983-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
27 Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16(24): 2963-2970 [PMID: 20572298 DOI: 10.3748/wjg.v16.i24.2963] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
28 Iida S, Miki Y, Ono K, Akahira J, Suzuki T, Ishida K, Watanabe M, Sasano H. Novel classification based on immunohistochemistry combined with hierarchical clustering analysis in non-functioning neuroendocrine tumor patients. Cancer Sci 2010;101:2278-85. [PMID: 20682006 DOI: 10.1111/j.1349-7006.2010.01657.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
29 Cervia D, Catalani E, Dal Monte M, Casini G. Vascular endothelial growth factor in the ischemic retina and its regulation by somatostatin: VEGF response to retinal ischemia. Journal of Neurochemistry 2012;120:818-29. [DOI: 10.1111/j.1471-4159.2011.07622.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
30 Tal-Gan Y, Hurevich M, Klein S, Ben-Shimon A, Rosenthal D, Hazan C, Shalev DE, Niv MY, Levitzki A, Gilon C. Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt). J Med Chem 2011;54:5154-64. [PMID: 21650457 DOI: 10.1021/jm2003969] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
31 Troxler T, Hurth K, Mattes H, Prashad M, Schoeffter P, Langenegger D, Enz A, Hoyer D. Discovery of novel non-peptidic β-alanine piperazine amide derivatives and their optimization to achiral, easily accessible, potent and selective somatostatin sst1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2009;19:1305-9. [DOI: 10.1016/j.bmcl.2009.01.072] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
32 Rubio A, Ávila J, de Lecea L. Cortistatin as a therapeutic target in inflammation. Expert Opinion on Therapeutic Targets 2006;11:1-9. [DOI: 10.1517/14728222.11.1.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
33 Beierle J, Horne W, van Maarseveen J, Waser B, Reubi J, Ghadiri M. Conformationally Homogeneous Heterocyclic Pseudotetrapeptides as Three‐Dimensional Scaffolds for Rational Drug Design: Receptor‐Selective Somatostatin Analogues. Angew Chem 2009;121:4819-23. [DOI: 10.1002/ange.200805901] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
34 Barbieri F, Bajetto A, Pattarozzi A, Gatti M, Würth R, Thellung S, Corsaro A, Villa V, Nizzari M, Florio T. Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept 2013;2013:926295. [PMID: 23476673 DOI: 10.1155/2013/926295] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
35 Annunziata M, Luque RM, Durán-Prado M, Baragli A, Grande C, Volante M, Gahete MD, Deltetto F, Camanni M, Ghigo E, Castaño JP, Granata R. Somatostatin and somatostatin analogues reduce PDGF-induced endometrial cell proliferation and motility. Hum Reprod 2012;27:2117-29. [PMID: 22588000 DOI: 10.1093/humrep/des144] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
36 Douillard-Guilloux G, Lewis D, Seney ML, Sibille E. Decrease in somatostatin-positive cell density in the amygdala of females with major depression. Depress Anxiety. 2017;34:68-78. [PMID: 27557481 DOI: 10.1002/da.22549] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
37 Trainor BC, Hofmann HA. Somatostatin and somatostatin receptor gene expression in dominant and subordinate males of an African cichlid fish. Behav Brain Res 2007;179:314-20. [PMID: 17374406 DOI: 10.1016/j.bbr.2007.02.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
38 Prasad S, Mathur A, Sharma R, Gupta N, Ahuja R, Jaggi M, Singh AT, Mukherjee R. Octapeptide Analogs of Somatostatin Containing α,α-Dialkylated Amino Acids with Potent Anticancer Activity. Int J Pept Res Ther 2006;12:179-85. [DOI: 10.1007/s10989-005-9005-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
39 Najib S, Saint-Laurent N, Estève JP, Schulz S, Boutet-Robinet E, Fourmy D, Lättig J, Mollereau C, Pyronnet S, Susini C, Bousquet C. A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85 to filamin A negatively controls the PI3K pathway. Mol Cell Biol 2012;32:1004-16. [PMID: 22203038 DOI: 10.1128/MCB.06252-11] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
40 Zhao J, Wang S, Han S, Kim SH, Kusnetzow AK, Nguyen J, Rico-Bautista E, Tan H, Betz SF, Scott Struthers R, Zhu Y. Discovery of nonpeptide 3,4-dihydroquinazoline-4-carboxamides as potent and selective sst2 agonists. Bioorg Med Chem Lett 2020;30:127391. [PMID: 32738999 DOI: 10.1016/j.bmcl.2020.127391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Florio T. Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. Mol Cell Endocrinol. 2008;286:40-48. [PMID: 17913342 DOI: 10.1016/j.mce.2007.08.012] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
42 Demmer O, Frank AO, Kessler H. Design of Cyclic Peptides. In: Jensen KJ, editor. Peptide and Protein Design for Biopharmaceutical Applications. Chichester: John Wiley & Sons, Ltd; 2009. pp. 133-76. [DOI: 10.1002/9780470749708.ch4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
43 Pelay-Gimeno M, Glas A, Koch O, Grossmann TN. Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes. Angew Chem Int Ed Engl 2015;54:8896-927. [PMID: 26119925 DOI: 10.1002/anie.201412070] [Cited by in Crossref: 366] [Cited by in F6Publishing: 322] [Article Influence: 61.0] [Reference Citation Analysis]
44 Brom M, Joosten L, Oyen WJ, Gotthardt M, Boerman OC. Improved labelling of DTPA- and DOTA-conjugated peptides and antibodies with 111In in HEPES and MES buffer. EJNMMI Res 2012;2:4. [PMID: 22284727 DOI: 10.1186/2191-219X-2-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
45 Wu Y, Hu J, Long X, Pan Y, Mu J, Park KY, Zhao X. Lactobacillus plantarum ZS62 Alleviates Alcohol-Induced Gastric Injury in Mice via an Anti-Oxidative Mechanism. Drug Des Devel Ther 2021;15:1667-76. [PMID: 33911852 DOI: 10.2147/DDDT.S292243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Gradiz R, Silva HC, Carvalho L, Botelho MF, Mota-Pinto A. MIA PaCa-2 and PANC-1 - pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors. Sci Rep 2016;6:21648. [PMID: 26884312 DOI: 10.1038/srep21648] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 13.0] [Reference Citation Analysis]
47 Reubi JC, Schonbrunn A. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci 2013;34:676-88. [PMID: 24183675 DOI: 10.1016/j.tips.2013.10.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 7.6] [Reference Citation Analysis]
48 Culler MD, Oberg K, Arnold R, Krenning EP, Sevilla I, Díaz JA. Somatostatin analogs for the treatment of neuroendocrine tumors. Cancer Metastasis Rev. 2011;30 Suppl 1:9-17. [PMID: 21369878 DOI: 10.1007/s10555-011-9293-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
49 Erchegyi J, Cescato R, Grace CR, Waser B, Piccand V, Hoyer D, Riek R, Rivier JE, Reubi JC. Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues. J Med Chem 2009;52:2733-46. [PMID: 19351180 DOI: 10.1021/jm801314f] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
50 Erchegyi J, Grace CR, Samant M, Cescato R, Piccand V, Riek R, Reubi JC, Rivier JE. Ring size of somatostatin analogues (ODT-8) modulates receptor selectivity and binding affinity. J Med Chem 2008;51:2668-75. [PMID: 18410084 DOI: 10.1021/jm701444y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
51 Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010;139:742-53, 753.e1. [PMID: 20637207 DOI: 10.1053/j.gastro.2010.07.002] [Cited by in Crossref: 116] [Cited by in F6Publishing: 105] [Article Influence: 10.5] [Reference Citation Analysis]
52 Bathula SR, Akondi SM, Mainkar PS, Chandrasekhar S. “Pruning of biomolecules and natural products (PBNP)”: an innovative paradigm in drug discovery. Org Biomol Chem 2015;13:6432-48. [DOI: 10.1039/c5ob00403a] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
53 Ben-Shlomo A, Pichurin O, Khalafi R, Zhou C, Chesnokova V, Ren SG, Liu NA, Melmed S. Constitutive somatostatin receptor subtype 2 activity attenuates GH synthesis. Endocrinology 2013;154:2399-409. [PMID: 23696564 DOI: 10.1210/en.2013-1132] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
54 Schuelert N, Just S, Kuelzer R, Corradini L, Gorham LC, Doods H. The somatostatin receptor 4 agonist J-2156 reduces mechanosensitivity of peripheral nerve afferents and spinal neurons in an inflammatory pain model. Eur J Pharmacol 2015;746:274-81. [PMID: 25445035 DOI: 10.1016/j.ejphar.2014.11.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
55 Strosberg J. Neuroendocrine tumours of the small intestine. Best Pract Res Clin Gastroenterol. 2012;26:755-773. [PMID: 23582917 DOI: 10.1016/j.bpg.2012.12.002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 6.9] [Reference Citation Analysis]
56 Berardi R, Partelli S, Cascinu S, Falconi M. Somatostatin analogs: is one better than other? Ther Adv Med Oncol 2017;9:817-9. [PMID: 29449900 DOI: 10.1177/1758834017741073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Pöll F, Lehmann D, Illing S, Ginj M, Jacobs S, Lupp A, Stumm R, Schulz S. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol Endocrinol 2010;24:436-46. [PMID: 20051480 DOI: 10.1210/me.2009-0315] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 5.9] [Reference Citation Analysis]
58 Wanka L, Iqbal K, Schreiner PR. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev 2013;113:3516-604. [PMID: 23432396 DOI: 10.1021/cr100264t] [Cited by in Crossref: 332] [Cited by in F6Publishing: 203] [Article Influence: 41.5] [Reference Citation Analysis]
59 Cervia D, Langenegger D, Schuepbach E, Cammalleri M, Schoeffter P, Schmid HA, Bagnoli P, Hoyer D. Binding and functional properties of the novel somatostatin analogue KE 108 at native mouse somatostatin receptors. Neuropharmacology 2005;48:881-93. [PMID: 15829258 DOI: 10.1016/j.neuropharm.2004.12.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
60 Zhao R, Zhang R, Li W, Liao Y, Tang J, Miao Q, Hao W. Genome-wide DNA methylation patterns in discordant sib pairs with alcohol dependence. Asia Pac Psychiatry 2013;5:39-50. [PMID: 23857790 DOI: 10.1111/appy.12010] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
61 Dicitore A, Saronni D, Gaudenzi G, Carra S, Cantone MC, Borghi MO, Persani L, Vitale G. Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines. J Endocrinol Invest 2021. [PMID: 34128215 DOI: 10.1007/s40618-021-01609-1] [Reference Citation Analysis]
62 Theodoropoulou M, Tichomirowa MA, Sievers C, Yassouridis A, Arzberger T, Hougrand O, Deprez M, Daly AF, Petrossians P, Pagotto U, Beckers A, Stalla GK. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. Int J Cancer 2009;125:2122-6. [PMID: 19637311 DOI: 10.1002/ijc.24602] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
63 Saif MW. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Opinion on Pharmacotherapy 2016;17:443-56. [DOI: 10.1517/14656566.2016.1127914] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
64 Parry JJ, Chen R, Andrews R, Lears KA, Rogers BE. Identification of critical residues involved in ligand binding and G protein signaling in human somatostatin receptor subtype 2. Endocrinology 2012;153:2747-55. [PMID: 22495673 DOI: 10.1210/en.2011-1662] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
65 Somvanshi RK, Billova S, Kharmate G, Rajput PS, Kumar U. C-tail mediated modulation of somatostatin receptor type-4 homo- and heterodimerizations and signaling. Cell Signal 2009;21:1396-414. [PMID: 19426801 DOI: 10.1016/j.cellsig.2009.04.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
66 Papadakis GZ, Karantanas AH, Marias K, Millo C. Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). Eur J Radiol 2021;143:109932. [PMID: 34482177 DOI: 10.1016/j.ejrad.2021.109932] [Reference Citation Analysis]
67 Catalani E, De Palma C, Perrotta C, Cervia D. Current Evidence for a Role of Neuropeptides in the Regulation of Autophagy. Biomed Res Int 2017;2017:5856071. [PMID: 28593174 DOI: 10.1155/2017/5856071] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
68 Hernández B, Carelli C, Coïc YM, De Coninck J, Ghomi M. Vibrational analysis of amino acids and short peptides in aqueous media. V. The effect of the disulfide bridge on the structural features of the peptide hormone somatostatin-14. J Phys Chem B 2009;113:12796-803. [PMID: 19708669 DOI: 10.1021/jp904737v] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
69 Michael M, Garcia-Carbonero R, Weber MM, Lombard-Bohas C, Toumpanakis C, Hicks RJ. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review. Oncologist 2017;22:272-85. [PMID: 28220021 DOI: 10.1634/theoncologist.2016-0305] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
70 Zatelli MC, Ambrosio MR, Bondanelli M, degli Uberti EC. In vitro testing of new somatostatin analogs on pituitary tumor cells. Molecular and Cellular Endocrinology 2008;286:187-91. [DOI: 10.1016/j.mce.2007.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
71 Pecere T, Ponterio E, Di Iorio E, Carli M, Fassan M, Santoro L, Bissaro M, Bernabè G, Moro S, Castagliuolo I, Palù G. On the mechanism of tumor cell entry of aloe-emodin, a natural compound endowed with anticancer activity. Int J Cancer 2021;149:1129-36. [PMID: 33990938 DOI: 10.1002/ijc.33686] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Durán-prado M, Gahete MD, Martínez-fuentes AJ, Luque RM, Quintero A, Webb SM, Benito-lópez P, Leal A, Schulz S, Gracia-navarro F, Malagón MM, Castaño JP. Identification and Characterization of Two Novel Truncated but Functional Isoforms of the Somatostatin Receptor Subtype 5 Differentially Present in Pituitary Tumors. The Journal of Clinical Endocrinology & Metabolism 2009;94:2634-43. [DOI: 10.1210/jc.2008-2564] [Cited by in Crossref: 99] [Cited by in F6Publishing: 87] [Article Influence: 8.3] [Reference Citation Analysis]
73 Luo R, Guo Y, Cao D, Pickar JG, Li L, Wang J, Zhao Y. Local effects of octreotide on glutamate-evoked activation of Aδ and C afferent fibers in rat hairy skin. Brain Research 2010;1322:50-8. [DOI: 10.1016/j.brainres.2010.01.058] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
74 Low MJ. Clinical endocrinology and metabolism. The somatostatin neuroendocrine system: physiology and clinical relevance in gastrointestinal and pancreatic disorders. Best Pract Res Clin Endocrinol Metab. 2004;18:607-622. [PMID: 15533778 DOI: 10.1016/j.beem.2004.08.005] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 4.4] [Reference Citation Analysis]
75 Durán-prado M, Saveanu A, Luque RM, Gahete MD, Gracia-navarro F, Jaquet P, Dufour H, Malagón MM, Culler MD, Barlier A, Castaño JP. A Potential Inhibitory Role for the New Truncated Variant of Somatostatin Receptor 5, sst5TMD4, in Pituitary Adenomas Poorly Responsive to Somatostatin Analogs. The Journal of Clinical Endocrinology & Metabolism 2010;95:2497-502. [DOI: 10.1210/jc.2009-2247] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 5.9] [Reference Citation Analysis]
76 Pintér E, Helyes Z, Szolcsányi J. Inhibitory effect of somatostatin on inflammation and nociception. Pharmacology & Therapeutics 2006;112:440-56. [DOI: 10.1016/j.pharmthera.2006.04.010] [Cited by in Crossref: 152] [Cited by in F6Publishing: 147] [Article Influence: 10.1] [Reference Citation Analysis]
77 Khatri B, Nuthakki VR, Chatterjee J. Strategies to Enhance Metabolic Stabilities. In: Goetz G, editor. Cyclic Peptide Design. New York: Springer; 2019. pp. 17-40. [DOI: 10.1007/978-1-4939-9504-2_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Callison JC Jr, Walker RC, Massion PP. Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and Therapeutics. J Lung Cancer 2011;10:69-76. [PMID: 25663834 DOI: 10.6058/jlc.2011.10.2.69] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
79 Hernández B, Coïc Y, Baron B, Kruglik SG, Pflüger F, Cohen R, Carelli C, Ghomi M, Wemmer DE. Low concentration structural dynamics of lanreotide and somatostatin-14: Structural Dynamics of Lanreotide and Somatostatin-14. Biopolymers 2014;101:1019-28. [DOI: 10.1002/bip.22491] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
80 Robertson CR, Flynn SP, White HS, Bulaj G. Anticonvulsant neuropeptides as drug leads for neurological diseases. Nat Prod Rep 2011;28:741-62. [PMID: 21340067 DOI: 10.1039/c0np00048e] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
81 Varecza Z, Elekes K, László T, Perkecz A, Pintér E, Sándor Z, Szolcsányi J, Keszthelyi D, Szabó A, Sándor K, Molnár TF, Szántó Z, Pongrácz JE, Helyes Z. Expression of the somatostatin receptor subtype 4 in intact and inflamed pulmonary tissues. J Histochem Cytochem 2009;57:1127-37. [PMID: 19687471 DOI: 10.1369/jhc.2009.953919] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
82 Afanador L, Yarosh H, Wang J, Ali SF, Angulo JA. Contrasting Effects of the Neuropeptides Substance P, Somatostatin, and Neuropeptide Y on the Methamphetamine-Induced Production of Striatal Nitric Oxide in Mice. J Drug Alcohol Res 2012;1:235604. [PMID: 25383232 DOI: 10.4303/jdar/235604] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
83 Shprakh ZS, Yartseva IV, Ignat’eva EV, Smirnova AP, Sushinina LP, Ustinkina SV, Smirnova LI, Bud’ko AP, Zimakova NI. Synthesis and Chemico-Pharmaceutical Characteristics of a Somatostatin Analog with Antitumor Activity. Pharm Chem J 2014;48:159-62. [DOI: 10.1007/s11094-014-1069-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
84 Zarogoulidis K, Eleftheriadou E, Kontakiotis T, Gerasimou G, Zarogoulidis P, Sapardanis I, Galaktidou G, Sakkas L, Gotzamani-Psarrakou A, Karatzas N. Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients. Lung Cancer 2012;76:84-8. [PMID: 22018594 DOI: 10.1016/j.lungcan.2011.09.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
85 Dal Monte M, Martini D, Ristori C, Azara D, Armani C, Balbarini A, Bagnoli P. Hypoxia effects on proangiogenic factors in human umbilical vein endothelial cells: functional role of the peptide somatostatin. Naunyn-Schmiedeberg's Arch Pharmacol 2011;383:593-612. [DOI: 10.1007/s00210-011-0625-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
86 Wang J, Cao DY, Guo Y, Ma SJ, Luo R, Pickar JG, Zhao Y. Octreotide inhibits capsaicin-induced activation of C and Aδ afferent fibres in rat hairy skin in vivo. Clin Exp Pharmacol Physiol 2011;38:521-7. [PMID: 21595740 DOI: 10.1111/j.1440-1681.2011.05542.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
87 Ristori C, Ferretti ME, Pavan B, Cervellati F, Casini G, Catalani E, Dal Monte M, Biondi C. Adenylyl cyclase/cAMP system involvement in the antiangiogenic effect of somatostatin in the retina. Results from transgenic mice. Neurochem Res 2008;33:1247-55. [PMID: 18270825 DOI: 10.1007/s11064-007-9576-6] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
88 Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies. The Journal of Clinical Endocrinology & Metabolism 2009;94:1500-8. [DOI: 10.1210/jc.2008-2332] [Cited by in Crossref: 133] [Cited by in F6Publishing: 119] [Article Influence: 11.1] [Reference Citation Analysis]
89 Nagel F, Doll C, Pöll F, Kliewer A, Schröder H, Schulz S. Structural determinants of agonist-selective signaling at the sst(2A) somatostatin receptor. Mol Endocrinol 2011;25:859-66. [PMID: 21330405 DOI: 10.1210/me.2010-0407] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
90 Zhao F, Zhou H, Li S, Fang Q, Luo Y, Hickford JGH. Growth and carcass trait association with variation in the somatostatin receptor 1 (SSTR1) gene in New Zealand Romney sheep. New Zealand Journal of Agricultural Research 2017;61:477-86. [DOI: 10.1080/00288233.2017.1415942] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
91 Albada HB, Wieberneit F, Dijkgraaf I, Harvey JH, Whistler JL, Stoll R, Metzler-nolte N, Fish RH. The Chemoselective Reactions of Tyrosine-Containing G-Protein-Coupled Receptor Peptides with [Cp*Rh(H 2 O) 3 ](OTf) 2 , Including 2D NMR Structures and the Biological Consequences. J Am Chem Soc 2012;134:10321-4. [DOI: 10.1021/ja303010k] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
92 Eberle AN, Mild G. Receptor-mediated tumor targeting with radiopeptides: Part 1. General principles and methods. Journal of Receptors and Signal Transduction 2009;29:1-37. [DOI: 10.1080/10799890902732823] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
93 邵国庆, 张南征. 生长抑素对裸鼠人胃癌种植瘤内VEGF和bFGF表达的影响. 世界华人消化杂志 2014; 22(36): 5659-5664 [DOI: 10.11569/wcjd.v22.i36.5659] [Reference Citation Analysis]
94 Lears KA, Parry JJ, Andrews R, Nguyen K, Wadas TJ, Rogers BE. Adenoviral-mediated imaging of gene transfer using a somatostatin receptor-cytosine deaminase fusion protein. Cancer Gene Ther 2015;22:215-21. [PMID: 25837665 DOI: 10.1038/cgt.2015.14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Kumar U, Singh S. Role of Somatostatin in the Regulation of Central and Peripheral Factors of Satiety and Obesity. Int J Mol Sci 2020;21:E2568. [PMID: 32272767 DOI: 10.3390/ijms21072568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
96 Kuil J, Velders AH, van Leeuwen FW. Multimodal tumor-targeting peptides functionalized with both a radio- and a fluorescent label. Bioconjug Chem 2010;21:1709-19. [PMID: 20812730 DOI: 10.1021/bc100276j] [Cited by in Crossref: 89] [Cited by in F6Publishing: 81] [Article Influence: 8.9] [Reference Citation Analysis]
97 Chen S, Gfeller D, Buth SA, Michielin O, Leiman PG, Heinis C. Improving binding affinity and stability of peptide ligands by substituting glycines with D-amino acids. Chembiochem 2013;14:1316-22. [PMID: 23828687 DOI: 10.1002/cbic.201300228] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
98 Kiseljak-Vassiliades K, Xu M, Mills TS, Smith EE, Silveira LJ, Lillehei KO, Kerr JM, Kleinschmidt-DeMasters BK, Wierman ME. Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors. Mol Cell Endocrinol 2015;417:73-83. [PMID: 26391562 DOI: 10.1016/j.mce.2015.09.016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
99 Ameri P, Gatto F, Arvigo M, Villa G, Resmini E, Minuto F, Murialdo G, Ferone D. Somatostatin receptor scintigraphy in thoracic diseases. J Endocrinol Invest 2007;30:889-902. [DOI: 10.1007/bf03349233] [Cited by in Crossref: 9] [Article Influence: 1.3] [Reference Citation Analysis]
100 Sawai Y, Yamane T, Ikeuchi M, Kawaguchi S, Yamada M, Yamano M. Process for the Preparation of an Amorphous, Peptide-like Diabetes Drug: Approach to a Chromatography-Free Process. Org Process Res Dev 2010;14:1110-7. [DOI: 10.1021/op100084r] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
101 Daeppen C, Kaiser M, Neuburger M, Gademann K. Preparation of Antimalarial Endoperoxides by a Formal [2 + 2 + 2] Cycloaddition. Org Lett 2015;17:5420-3. [PMID: 26491785 DOI: 10.1021/acs.orglett.5b02773] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
102 Rossi V, Di Zazzo E, Galasso G, De Rosa C, Abbondanza C, Sinisi AA, Altucci L, Migliaccio A, Castoria G. Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells. Front Pharmacol. 2019;10:28. [PMID: 30828298 DOI: 10.3389/fphar.2019.00028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
103 Rinke A, Krug S. Neuroendocrine tumours – Medical therapy: Biological. Best Practice & Research Clinical Endocrinology & Metabolism 2016;30:79-91. [DOI: 10.1016/j.beem.2015.09.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
104 Tatsi A, Maina T, Cescato R, Waser B, Krenning EP, de Jong M, Cordopatis P, Reubi JC, Nock BA. [DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting. Eur J Med Chem 2014;73:30-7. [PMID: 24378707 DOI: 10.1016/j.ejmech.2013.12.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
105 Ben-Shlomo A, Wawrowsky KA, Proekt I, Wolkenfeld NM, Ren SG, Taylor J, Culler MD, Melmed S. Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem 2005;280:24011-21. [PMID: 15857828 DOI: 10.1074/jbc.M501998200] [Cited by in Crossref: 45] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
106 Schonbrunn A. Somatostatin Receptors. Encyclopedia of Biological Chemistry. Elsevier; 2004. pp. 55-60. [DOI: 10.1016/b0-12-443710-9/00631-1] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
107 Cammalleri M, Cervia D, Langenegger D, Liu Y, Dal Monte M, Hoyer D, Bagnoli P. Somatostatin receptors differentially affect spontaneous epileptiform activity in mouse hippocampal slices. Eur J Neurosci 2004;20:2711-21. [PMID: 15548214 DOI: 10.1111/j.1460-9568.2004.03741.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
108 Durán-Prado M, Bucharles C, Gonzalez BJ, Vázquez-Martínez R, Martínez-Fuentes AJ, García-Navarro S, Rhodes SJ, Vaudry H, Malagón MM, Castaño JP. Porcine somatostatin receptor 2 displays typical pharmacological sst2 features but unique dynamics of homodimerization and internalization. Endocrinology 2007;148:411-21. [PMID: 17053026 DOI: 10.1210/en.2006-0920] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
109 Webb K, Rønnestad I. Regulation of Digestive Processes. In: Holt GJ, editor. Larval Fish Nutrition. Oxford: Wiley-Blackwell; 2011. pp. 265-82. [DOI: 10.1002/9780470959862.ch9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Yim CB, van der Wildt B, Dijkgraaf I, Joosten L, Eek A, Versluis C, Rijkers DT, Boerman OC, Liskamp RM. Spacer effects on in vivo properties of DOTA-conjugated dimeric [Tyr3]octreotate peptides synthesized by a "Cu(I)-click" and "sulfo-click" ligation method. Chembiochem 2011;12:750-60. [PMID: 21328514 DOI: 10.1002/cbic.201000639] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
111 Farrell SR, Rankin DR, Brecha NC, Barnes S. Somatostatin receptor subtype 4 modulates L-type calcium channels via Gβγ and PKC signaling in rat retinal ganglion cells. Channels (Austin) 2014;8:519-27. [PMID: 25483286 DOI: 10.4161/19336950.2014.967623] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
112 Grant M, Kumar U. The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. Regulatory Peptides 2010;159:3-8. [DOI: 10.1016/j.regpep.2009.08.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
113 Lu YY, Gao JH, Zhao C, Wen SL, Tang CW, Wang YF. Cyclooxygenase-2 up-regulates hepatic somatostatin receptor 2 expression. Sci Rep 2018;8:11033. [PMID: 30038293 DOI: 10.1038/s41598-018-29349-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
114 Sizdahkhani S, Feldman MJ, Piazza MG, Ksendzovsky A, Edwards NA, Ray-Chaudhury A, Maric D, Merrill MJ, Pacak K, Zhuang Z, Chittiboina P. Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target. Sci Rep 2017;7:40822. [PMID: 28094316 DOI: 10.1038/srep40822] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
115 Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, Erchegyi J, Rivier J, Mäcke HR, Reubi JC. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA. 2006;103:16436-16441. [PMID: 17056720 DOI: 10.1073/pnas.0607761103] [Cited by in Crossref: 311] [Cited by in F6Publishing: 270] [Article Influence: 20.7] [Reference Citation Analysis]
116 Ovadia O, Greenberg S, Laufer B, Gilon C, Hoffman A, Kessler H. Improvement of drug-like properties of peptides: the somatostatin paradigm. Expert Opinion on Drug Discovery 2010;5:655-71. [DOI: 10.1517/17460441.2010.493935] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 4.5] [Reference Citation Analysis]
117 Testa C, D'addona D, Scrima M, Tedeschi AM, D'ursi AM, Bernhard C, Denat F, Bello C, Rovero P, Chorev M, Papini AM. Design, synthesis, and conformational studies of [DOTA]‐Octreotide analogs containing [1,2,3]triazolyl as a disulfide mimetic. Peptide Science 2018;110:e24071. [DOI: 10.1002/pep2.24071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 D’addona D, Carotenuto A, Novellino E, Piccand V, Reubi JC, Di Cianni A, Gori F, Papini AM, Ginanneschi M. Novel sst 5 -Selective Somatostatin Dicarba-Analogues: Synthesis and Conformation−Affinity Relationships. J Med Chem 2008;51:512-20. [DOI: 10.1021/jm070886i] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
119 Szolcsányi J, Bölcskei K, Szabó Á, Pintér E, Pethő G, Elekes K, Börzsei R, Almási R, Szűts T, Kéri G, Helyes Z. Analgesic effect of TT-232, a heptapeptide somatostatin analogue, in acute pain models of the rat and the mouse and in streptozotocin-induced diabetic mechanical allodynia. European Journal of Pharmacology 2004;498:103-9. [DOI: 10.1016/j.ejphar.2004.07.085] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
120 Noor A, Van Zuylekom JK, Rudd SE, Roselt PD, Haskali MB, Yan E, Wheatcroft M, Hicks RJ, Cullinane C, Donnelly PS. Imaging Somatostatin Positive Tumors with Tyr3-Octreotate/Octreotide Conjugated to Desferrioxamine B Squaramide Radiolabeled with either Zirconium-89 or Gallium-68. Bioconjug Chem 2021;32:1192-203. [PMID: 33788556 DOI: 10.1021/acs.bioconjchem.1c00109] [Reference Citation Analysis]
121 López-tobar E, Hernández B, Gómez J, Chenal A, Garcia-ramos JV, Ghomi M, Sanchez-cortes S. Anchoring Sites of Fibrillogenic Peptide Hormone Somatostatin-14 on Plasmonic Nanoparticles. J Phys Chem C 2015;119:8273-9. [DOI: 10.1021/acs.jpcc.5b00485] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
122 Bousquet C, Guillermet-Guibert J, Saint-Laurent N, Archer-Lahlou E, Lopez F, Fanjul M, Ferrand A, Fourmy D, Pichereaux C, Monsarrat B, Pradayrol L, Estève JP, Susini C. Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. EMBO J 2006;25:3943-54. [PMID: 16917505 DOI: 10.1038/sj.emboj.7601279] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
123 Rai U, Thrimawithana TR, Valery C, Young SA. Therapeutic uses of somatostatin and its analogues: Current view and potential applications. Pharmacol Ther 2015;152:98-110. [PMID: 25956467 DOI: 10.1016/j.pharmthera.2015.05.007] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 11.2] [Reference Citation Analysis]
124 Weiss H, Wirz B, Schweitzer A, Amstutz R, Perez M, Andres H, Metz Y, Gardiner J, Seebach D. ADME Investigations of Unnatural Peptides: Distribution of a14C-Labeledβ3-Octaarginine in Rats. C&B 2007;4:1413-37. [DOI: 10.1002/cbdv.200790121] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
125 Iwasawa C, Narita M, Tamura H. Regional and temporal regulation and role of somatostatin receptor subtypes in the mouse brain following systemic kainate-induced acute seizures. Neurosci Res 2019;149:38-49. [PMID: 30685491 DOI: 10.1016/j.neures.2019.01.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Danalev D, Borisova D, Yaneva S, Georgieva M, Balacheva A, Dzimbova T, Iliev I, Pajpanova T, Zaharieva Z, Givechev I, Naydenova E. Synthesis, in vitro biological activity, hydrolytic stability and docking of new analogs of BIM-23052 containing halogenated amino acids. Amino Acids 2020;52:1581-92. [PMID: 33215308 DOI: 10.1007/s00726-020-02915-3] [Reference Citation Analysis]
127 Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules 2020;25:E4012. [PMID: 32887456 DOI: 10.3390/molecules25174012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
128 Zatelli MC, Piccin D, Ambrosio MR, Bondanelli M, Uberti ECD. Antiproliferative effects of somatostatin analogs in pituitary adenomas. Pituitary 2006;9:27-34. [DOI: 10.1007/s11102-006-7822-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
129 Fleseriu M, Petersenn S. New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy. J Neurooncol 2013;114:1-11. [PMID: 23673515 DOI: 10.1007/s11060-013-1151-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
130 Capone S, Kieltsch I, Flögel O, Lelais G, Togni A, Seebach D. Electrophilic S -Trifluoromethylation of Cysteine Side Chains in α - and β -Peptides: Isolation of Trifluoro-methylated Sandostatin® (Octreotide) Derivatives. HCA 2008;91:2035-56. [DOI: 10.1002/hlca.200890217] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 5.6] [Reference Citation Analysis]
131 Hoyer D, Nunn C, Hannon J, Schoeffter P, Feuerbach D, Schuepbach E, Langenegger D, Bouhelal R, Hurth K, Neumann P, Troxler T, Pfaeffli P. SRA880, in vitro characterization of the first non-peptide somatostatin sst(1) receptor antagonist. Neurosci Lett 2004;361:132-5. [PMID: 15135911 DOI: 10.1016/j.neulet.2004.02.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
132 Melmed S, Kleinberg D. Pituitary Masses and Tumors. Williams Textbook of Endocrinology. Elsevier; 2016. pp. 232-99. [DOI: 10.1016/b978-0-323-29738-7.00009-5] [Cited by in Crossref: 13] [Article Influence: 2.6] [Reference Citation Analysis]
133 van der Spoel E, Jansen SW, Akintola AA, Ballieux BE, Cobbaert CM, Slagboom PE, Blauw GJ, Westendorp RGJ, Pijl H, Roelfsema F, van Heemst D. Growth hormone secretion is diminished and tightly controlled in humans enriched for familial longevity. Aging Cell 2016;15:1126-31. [PMID: 27605408 DOI: 10.1111/acel.12519] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 8.4] [Reference Citation Analysis]
134 Cakir M, Dworakowska D, Grossman A. Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways. J Cell Mol Med 2010;14:2570-84. [PMID: 20629989 DOI: 10.1111/j.1582-4934.2010.01125.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
135 de Lecea L, Castaño JP. Cortistatin: not just another somatostatin analog. Nat Rev Endocrinol 2006;2:356-7. [DOI: 10.1038/ncpendmet0219] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
136 Jansson S, Fredén Lindqvist J, Manhem K, Nilsson O, Rosén T, Herlitz H. Quiz page June 2015: a young woman with hypertension. Am J Kidney Dis 2015;65:A17-9. [PMID: 26003613 DOI: 10.1053/j.ajkd.2015.01.027] [Reference Citation Analysis]
137 Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest 2009;119:3189-202. [PMID: 19884662 DOI: 10.1172/JCI39375] [Cited by in Crossref: 375] [Cited by in F6Publishing: 164] [Article Influence: 31.3] [Reference Citation Analysis]
138 Luger A. Hyperglycemia in pasireotide-treated patients with acromegaly and its treatment. Endocrine 2016;54:1-2. [DOI: 10.1007/s12020-016-1029-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
139 Öberg K. Somatostatin analog octreotide LAR ® in gastro–entero–pancreatic tumors. Expert Review of Anticancer Therapy 2014;9:557-66. [DOI: 10.1586/era.09.26] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
140 Horne WS. Peptide and peptoid foldamers in medicinal chemistry. Expert Opinion on Drug Discovery 2011;6:1247-62. [DOI: 10.1517/17460441.2011.632002] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 8.2] [Reference Citation Analysis]
141 Shupe T, Petersen BE. Potential applications for cell regulatory factors in liver progenitor cell therapy. Int J Biochem Cell Biol 2011;43:214-21. [PMID: 20851776 DOI: 10.1016/j.biocel.2010.09.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
142 Ou Y, Liu R, Wei N, Li X, Qiang O, Huang W, Tang C. Effects of octreotide on nitric oxide synthase expression in the small intestine of high fat diet-induced obese rats. Obes Res Clin Pract 2012;6:e263-346. [PMID: 24331588 DOI: 10.1016/j.orcp.2011.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
143 Dang CN, Trainer P. Pharmacological management of Cushing's syndrome: an update. Arq Bras Endocrinol Metab 2007;51:1339-48. [DOI: 10.1590/s0004-27302007000800020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
144 Hara K, Shigemori T, Kuroda K, Ueda M. Membrane-displayed somatostatin activates somatostatin receptor subtype-2 heterologously produced in Saccharomyces cerevisiae. AMB Express 2012;2:63. [PMID: 23193953 DOI: 10.1186/2191-0855-2-63] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
145 Hu Y, Ye Z, Wang F, Qin Y, Xu X, Yu X, Ji S. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. Front Endocrinol (Lausanne) 2021;12:679000. [PMID: 34093445 DOI: 10.3389/fendo.2021.679000] [Reference Citation Analysis]
146 Daunt M, Dale O, Smith PA. Somatostatin inhibits oxidative respiration in pancreatic beta-cells. Endocrinology 2006;147:1527-35. [PMID: 16357046 DOI: 10.1210/en.2005-0873] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
147 Öberg K. Biotherapies for GEP-NETs. Best Pract Res Clin Gastroenterol. 2012;26:833-841. [PMID: 23582922 DOI: 10.1016/j.bpg.2013.01.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
148 Feelders RA, Hofland LJ, Kwekkeboom DJ, Lamberts S, de Herder WW. Neuroendocrine Tumors. Handbook of Neuroendocrinology. Elsevier; 2012. pp. 761-78. [DOI: 10.1016/b978-0-12-375097-6.10035-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
149 Biron E, Chatterjee J, Ovadia O, Langenegger D, Brueggen J, Hoyer D, Schmid HA, Jelinek R, Gilon C, Hoffman A, Kessler H. Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues. Angew Chem Int Ed Engl 2008;47:2595-9. [PMID: 18297660 DOI: 10.1002/anie.200705797] [Cited by in Crossref: 248] [Cited by in F6Publishing: 218] [Article Influence: 19.1] [Reference Citation Analysis]
150 Ng XW, Chung YH, Piston DW. Intercellular Communication in the Islet of Langerhans in Health and Disease. Compr Physiol 2021;11:2191-225. [PMID: 34190340 DOI: 10.1002/cphy.c200026] [Reference Citation Analysis]
151 Dicuonzo F, Purciariello S, De Marco A, Guastamacchia E, Triggiani V. Inoperable Giant Growth Hormone-secreting Pituitary Adenoma: Radiological Aspects, Clinical Management and Pregnancy Outcome. EMIDDT 2019;19:214-20. [DOI: 10.2174/1871530318666180807160712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
152 Cambiaghi V, Vitali E, Morone D, Peverelli E, Spada A, Mantovani G, Lania AG. Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line. Endocrine 2017;56:146-57. [DOI: 10.1007/s12020-016-1026-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
153 Thermos K, Bagnoli P, Epelbaum J, Hoyer D. The somatostatin sst1 receptor: an autoreceptor for somatostatin in brain and retina? Pharmacol Ther 2006;110:455-64. [PMID: 16274747 DOI: 10.1016/j.pharmthera.2005.09.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
154 Engin E, Stellbrink J, Treit D, Dickson CT. Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin: behavioral and neurophysiological evidence. Neuroscience 2008;157:666-76. [PMID: 18940236 DOI: 10.1016/j.neuroscience.2008.09.037] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 6.1] [Reference Citation Analysis]
155 Horváth K, Boros M, Bagoly T, Sándor V, Kilár F, Kemény A, Helyes Z, Szolcsányi J, Pintér E. Analgesic topical capsaicinoid therapy increases somatostatin-like immunoreactivity in the human plasma. Neuropeptides 2014;48:371-8. [PMID: 25455106 DOI: 10.1016/j.npep.2014.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
156 Grimberg A. Somatostatin and cancer: applying endocrinology to oncology. Cancer Biol Ther. 2004;3:731-733. [PMID: 15326367 DOI: 10.4161/cbt.3.8.1030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
157 Yamamoto J, Ohnuma K, Hatano R, Okamoto T, Komiya E, Yamazaki H, Iwata S, Dang NH, Aoe K, Kishimoto T, Yamada T, Morimoto C. Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma. Br J Cancer 2014;110:2232-45. [PMID: 24743707 DOI: 10.1038/bjc.2014.151] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
158 Yao CY, Gill M, Martens CA, Coy DH, Hsu WH. Somatostatin inhibits insulin release via SSTR2 in hamster clonal beta-cells and pancreatic islets. Regul Pept 2005;129:79-84. [PMID: 15927701 DOI: 10.1016/j.regpep.2005.01.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
159 Moncayo R. Reflections on the theory of "silver bullet" octreotide tracers: implications for ligand-receptor interactions in the age of peptides, heterodimers, receptor mosaics, truncated receptors, and multifractal analysis. EJNMMI Res 2011;1:9. [PMID: 22214590 DOI: 10.1186/2191-219X-1-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
160 Melmed S. Pituitary Medicine From Discovery to Patient-Focused Outcomes. J Clin Endocrinol Metab 2016;101:769-77. [PMID: 26908107 DOI: 10.1210/jc.2015-3653] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
161 Abdel-Hamid NM, Mohafez OM, Nazmy MH, Farhan A, Thabet K. The effect of co-administration of Lawsonia inermis extract and octreotide on experimental hepatocellular carcinoma. Environ Health Prev Med 2015;20:195-203. [PMID: 25726025 DOI: 10.1007/s12199-015-0451-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
162 Chen W, Ke JB, Wu HJ, Miao Y, Li F, Yang XL, Wang Z. Somatostatin receptor-mediated suppression of gabaergic synaptic transmission in cultured rat retinal amacrine cells. Neuroscience 2014;273:118-27. [PMID: 24846611 DOI: 10.1016/j.neuroscience.2014.05.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
163 Hernández B, Tinacci L, Coïc Y, Chenal A, Cohen R, Sanchez-cortes S, Ghomi M. Tryptophan Tight Binding to Gold Nanoparticles Induces Drastic Changes in Indole Ring Raman Markers. J Phys Chem C 2018;122:13034-46. [DOI: 10.1021/acs.jpcc.8b02261] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
164 López-tobar E, Hernández B, Chenal A, Coïc Y, Gómez Santos J, Mejía-ospino E, Garcia-ramos JV, Ghomi M, Sanchez-cortes S. Large size citrate-reduced gold colloids appear as optimal SERS substrates for cationic peptides: Optimal gold colloids for SERS. J Raman Spectrosc 2017;48:30-7. [DOI: 10.1002/jrs.4976] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
165 Bhandari S, Watson N, Long E, Sharpe S, Zhong W, Xu SZ, Atkin SL. Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney. J Histochem Cytochem 2008;56:733-43. [PMID: 18443363 DOI: 10.1369/jhc.2008.950998] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
166 Guitot K, Larregola M, Pradhan TK, Vasse J, Lavielle S, Bertus P, Szymoniak J, Lequin O, Karoyan P. The Combination of Prolinoamino Acids and Cyclopropylamino Acids Leads to Fully Functionalized, Stable β-Turns in Water. ChemBioChem 2011;12:1039-42. [DOI: 10.1002/cbic.201000707] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
167 Zatelli MC, Ambrosio MR, Bondanelli M, Uberti ECD. Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds. Eur J Endocrinol 2007;156 Suppl 1:S29-35. [PMID: 17413185 DOI: 10.1530/eje.1.02352] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
168 Gatto F, Hofland LJ. The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocr Relat Cancer 2011;18:R233-51. [PMID: 22135243 DOI: 10.1530/ERC-10-0334] [Cited by in Crossref: 57] [Cited by in F6Publishing: 22] [Article Influence: 5.7] [Reference Citation Analysis]
169 Guillermet-guibert J, Saint-laurent N, Davenne L, Rochaix P, Cuvillier O, Culler MD, Pradayrol L, Buscail L, Susini C, Bousquet C. Novel synergistic mechanism for sst2 somatostatin and TNFα receptors to induce apoptosis: crosstalk between NF-κB and JNK pathways. Cell Death Differ 2007;14:197-208. [DOI: 10.1038/sj.cdd.4401939] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
170 Holliday ND, Tough IR, Cox HM. A functional comparison of recombinant and native somatostatin sst2 receptor variants in epithelia. Br J Pharmacol 2007;152:132-40. [PMID: 17603546 DOI: 10.1038/sj.bjp.0707365] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
171 Lehmann A, Kliewer A, Günther T, Nagel F, Schulz S. Identification of Phosphorylation Sites Regulating sst3 Somatostatin Receptor Trafficking. Mol Endocrinol 2016;30:645-59. [PMID: 27101376 DOI: 10.1210/me.2015-1244] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
172 Varela N, Chorny A, Gonzalez-Rey E, Delgado M. Tuning inflammation with anti-inflammatory neuropeptides. Expert Opin Biol Ther 2007;7:461-78. [PMID: 17373898 DOI: 10.1517/14712598.7.4.461] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
173 Bandara N, Jacobson O, Mpoy C, Chen X, Rogers BE. Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent. Bioconjug Chem 2018;29:2448-54. [PMID: 29927587 DOI: 10.1021/acs.bioconjchem.8b00341] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
174 Cakir M, Dworakowska D, Grossman A. Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications. J Cell Mol Med 2010;14:2585-91. [PMID: 20629988 DOI: 10.1111/j.1582-4934.2010.01125_1.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
175 Pecori Giraldi F, Pagliardini L, Cassarino M, Martucci F, Sesta A, Castelli L, Montanari E, Schmid H, Cavagnini F. Stimulatory effect of SOM230 on human and rat adrenal corticosteroid secretion in vitro. General and Comparative Endocrinology 2012;178:436-9. [DOI: 10.1016/j.ygcen.2012.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
176 Rubin SJS, Tal-Gan Y, Gilon C, Qvit N. Conversion of Protein Active Regions into Peptidomimetic Therapeutic Leads Using Backbone Cyclization and Cycloscan - How to Do it Yourself! Curr Top Med Chem 2018;18:556-65. [PMID: 29773063 DOI: 10.2174/1568026618666180518094322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
177 Chung C. Management of neuroendocrine tumors. American Journal of Health-System Pharmacy 2016;73:1729-44. [DOI: 10.2146/ajhp150373] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
178 Laklai H, Laval S, Dumartin L, Rochaix P, Hagedorn M, Bikfalvi A, Le Guellec S, Delisle MB, Schally AV, Susini C, Pyronnet S, Bousquet C. Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proc Natl Acad Sci U S A 2009;106:17769-74. [PMID: 19805200 DOI: 10.1073/pnas.0908674106] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
179 Lau A, Bourkas M, Lu YQQ, Ostrowski LA, Weber-Adrian D, Figueiredo C, Arshad H, Shoaei SZS, Morrone CD, Matan-Lithwick S, Abraham KJ, Wang H, Schmitt-Ulms G. Functional Amyloids and their Possible Influence on Alzheimer Disease. Discoveries (Craiova) 2017;5:e79. [PMID: 32309597 DOI: 10.15190/d.2017.9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
180 Feytens D, De Vlaeminck M, Cescato R, Tourwé D, Reubi JC. Highly Potent 4-Amino-indolo[2,3- c ]azepin-3-one-Containing Somatostatin Mimetics with a Range of sst Receptor Selectivities. J Med Chem 2009;52:95-104. [DOI: 10.1021/jm801205x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
181 Blakeney JS, Reid RC, Le GT, Fairlie DP. Nonpeptidic Ligands for Peptide-Activated G Protein-Coupled Receptors. Chem Rev 2007;107:2960-3041. [DOI: 10.1021/cr050984g] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 5.3] [Reference Citation Analysis]
182 Ding Y, Fan J, Li W, Peng Y, Yang R, Deng L, Fu Q. The effect of albumin fusion structure on the production and bioactivity of the somatostatin-28 fusion protein in Pichia pastoris. Journal of Industrial Microbiology and Biotechnology 2014;41:997-1006. [DOI: 10.1007/s10295-014-1440-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
183 Sándor K, Elekes K, Szabó A, Pintér E, Engström M, Wurster S, Szolcsányi J, Helyes Z. Analgesic effects of the somatostatin sst4 receptor selective agonist J-2156 in acute and chronic pain models. Eur J Pharmacol 2006;539:71-5. [PMID: 16697366 DOI: 10.1016/j.ejphar.2006.03.082] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
184 Koopmans KP, Glaudemans AW. Rationale for the use of radiolabelled peptides in diagnosis and therapy. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:S4-10. [PMID: 22388630 DOI: 10.1007/s00259-011-2038-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
185 Lee MS, O'Neil BH. Summary of emerging personalized medicine in neuroendocrine tumors: are we on track? J Gastrointest Oncol 2016;7:804-18. [PMID: 27747094 DOI: 10.21037/jgo.2016.08.05] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
186 Biron E, Chatterjee J, Ovadia O, Langenegger D, Brueggen J, Hoyer D, Schmid H, Jelinek R, Gilon C, Hoffman A, Kessler H. Die Verbesserung der oralen Bioverfügbarkeit von Peptiden durch multiple N-Methylierung: Somatostatin-Analoga. Angew Chem 2008;120:2633-7. [DOI: 10.1002/ange.200705797] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
187 Caumes C, Hjelmgaard T, Roy O, Reynaud M, Servent D, Taillefumier C, Faure S. Synthesis and binding affinities for sst receptors of cyclic peptoid SRIF-mimetics. Med Chem Commun 2012;3:1531-5. [DOI: 10.1039/c2md20265d] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
188 Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C. Antitumor effects of somatostatin. Mol Cell Endocrinol. 2008;286:230-237. [PMID: 18359151 DOI: 10.1016/j.mce.2008.02.002] [Cited by in Crossref: 104] [Cited by in F6Publishing: 101] [Article Influence: 8.0] [Reference Citation Analysis]
189 Tuvia S, Pelled D, Marom K, Salama P, Levin-Arama M, Karmeli I, Idelson GH, Landau I, Mamluk R. A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms. Pharm Res 2014;31:2010-21. [PMID: 24558008 DOI: 10.1007/s11095-014-1303-9] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 8.9] [Reference Citation Analysis]
190 Balaev AN, Osipov VN, Khachatryan DS. Synthetic Peptide Analogs of Somatostatin: Trends in the Synthesis of and Prospects in the Search for New Anticancer Drugs. Pharm Chem J 2015;49:345-51. [DOI: 10.1007/s11094-015-1284-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
191 Wu B, Qi R, Li B, Yuan T, Liu H, He J, Lin Z, Li W, Fu Y, Niu D. Effect of active immunization against a recombinant mouse granulocyte-macrophage colony-stimulating factor/somatostatin fusion protein on the growth of mice. Mol Biol Rep 2012;39:6773-9. [DOI: 10.1007/s11033-012-1502-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
192 Costanzi E, Simioni C, Conti I, Laface I, Varano G, Brenna C, Neri LM. Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives. J Cell Physiol 2021;236:2505-18. [PMID: 32989768 DOI: 10.1002/jcp.30062] [Reference Citation Analysis]
193 Cammalleri M, Cervia D, Dal Monte M, Martini D, Langenegger D, Fehlmann D, Feuerbach D, Pavan B, Hoyer D, Bagnoli P. Compensatory changes in the hippocampus of somatostatin knockout mice: upregulation of somatostatin receptor 2 and its function in the control of bursting activity and synaptic transmission. Eur J Neurosci 2006;23:2404-22. [PMID: 16706848 DOI: 10.1111/j.1460-9568.2006.04770.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
194 Guillermet-Guibert J, Lahlou H, Pyronnet S, Bousquet C, Susini C. Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects. Best Pract Res Clin Gastroenterol 2005;19:535-51. [PMID: 16183526 DOI: 10.1016/j.bpg.2005.03.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
195 Martino MCD, Hofland LJ, Lamberts SW. Somatostatin and Somatostatin Receptors: from Basic Concepts to Clinical Applications. Neuroendocrinology - Pathological Situations and Diseases. Elsevier; 2010. pp. 255-80. [DOI: 10.1016/s0079-6123(10)82011-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
196 Gardiner J, Langenegger D, Hoyer D, Beck A, Mathad R, Seebach D. The Enantiomer of Octreotate Binds to All Five Somatostatin Receptors with Almost Equal Micromolar Affinity - A Comparison with SANDOSTATIN®. C&B 2008;5:1213-24. [DOI: 10.1002/cbdv.200890110] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
197 Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev 2011;32:247-71. [PMID: 21123741 DOI: 10.1210/er.2010-0002] [Cited by in Crossref: 165] [Cited by in F6Publishing: 148] [Article Influence: 15.0] [Reference Citation Analysis]
198 Kumar R, Gautam M, Prasoon P, Gupta S, Ray SB. Comparison of the peripheral antinociceptive effect of somatostatin with bupivacaine and morphine in the rodent postoperative pain model. Eur J Anaesthesiol 2018;35:955-65. [PMID: 29762151 DOI: 10.1097/EJA.0000000000000825] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Renner S, Popov M, Schuffenhauer A, Roth H, Breitenstein W, Marzinzik A, Lewis I, Krastel P, Nigsch F, Jenkins J, Jacoby E. Recent trends and observations in the design of high-quality screening collections. Future Medicinal Chemistry 2011;3:751-66. [DOI: 10.4155/fmc.11.15] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
200 Sabatino G, Guryanov I, Rombecchi A, Zanon J, Ricci A, Cabri W, Papini AM, Rovero P. Production of peptides as generic drugs: a patent landscape of octreotide. Expert Opinion on Therapeutic Patents 2016;26:485-95. [DOI: 10.1517/13543776.2016.1158810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
201 Feytens D, Cescato R, Reubi JC, Tourwé D. New sst4/5-selective somatostatin peptidomimetics based on a constrained tryptophan scaffold. J Med Chem 2007;50:3397-401. [PMID: 17559206 DOI: 10.1021/jm070246f] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
202 Ghosh M, Schonbrunn A. Differential temporal and spatial regulation of somatostatin receptor phosphorylation and dephosphorylation. J Biol Chem 2011;286:13561-73. [PMID: 21343287 DOI: 10.1074/jbc.M110.215723] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
203 Mikhaevich EI, Krasil’nikov MA. The Mechanism of Cytostatic Effect of a New Somatostatin Analog Cifetrelin on In Vitro Cultured MCF-7 Breast Carcinoma Cells. Bull Exp Biol Med 2013;154:669-72. [DOI: 10.1007/s10517-013-2026-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
204 Pavan B, Fiorini S, Dal Monte M, Lunghi L, Biondi C, Bagnoli P, Cervia D. Somatostatin coupling to adenylyl cyclase activity in the mouse retina. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:91-98. [PMID: 15309377 DOI: 10.1007/s00210-004-0950-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
205 Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther. 2004;102:61-85. [PMID: 15056499 DOI: 10.1016/j.pharmthera.2004.02.002] [Cited by in Crossref: 109] [Cited by in F6Publishing: 96] [Article Influence: 6.4] [Reference Citation Analysis]
206 Koyama M, Yin C, Ishii H, Sakuma Y, Kato M. Somatostatin inhibition of GnRH neuronal activity and the morphological relationship between GnRH and somatostatin neurons in rats. Endocrinology 2012;153:806-14. [PMID: 22147011 DOI: 10.1210/en.2011-1374] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
207 Gracia SR, Gaus K, Sewald N. Synthesis of chemically modified bioactive peptides: recent advances, challenges and developments for medicinal chemistry. Future Medicinal Chemistry 2009;1:1289-310. [DOI: 10.4155/fmc.09.97] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 4.2] [Reference Citation Analysis]
208 Gao J, Tong H, Huang Z, Liu R, Li X, Qiang O, Tang C. Affinity analysis of somatostatin and somatostatin receptor by surface plasmon resonance. Anal Methods 2013;5:3201. [DOI: 10.1039/c3ay26548j] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
209 De K, Bhowmik A, Behera A, Banerjee I, Ghosh MK, Misra M. Synthesis, radiolabeling, and preclinical evaluation of a new octreotide analog for somatostatin receptor-positive tumor scintigraphy: SOMATOSTATIN ANALOG FOR BRAIN TUMOR IMAGING. J Pept Sci 2012;18:720-30. [DOI: 10.1002/psc.2458] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
210 Pekošak A, Rotstein BH, Collier TL, Windhorst AD, Vasdev N, Poot AJ. Stereoselective 11 C Labeling of a “Native” Tetrapeptide by Using Asymmetric Phase-Transfer Catalyzed Alkylation Reactions: Stereoselective 11 C Labeling of a “Native” Tetrapeptide by Using Asymmetric Phase-Transfer Catalyzed Alkylation Reactions. Eur J Org Chem 2017;2017:1019-24. [DOI: 10.1002/ejoc.201601641] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
211 Lelais G, Seebach D. ?2-amino acids?syntheses, occurrence in natural products, and components of ?-peptides1,2. Biopolymers 2004;76:206-43. [DOI: 10.1002/bip.20088] [Cited by in Crossref: 259] [Cited by in F6Publishing: 217] [Article Influence: 15.2] [Reference Citation Analysis]
212 Somm E, Bonnet N, Zizzari P, Tolle V, Toulotte A, Jones R, Epelbaum J, Martinez A, Hüppi PS, Aubert ML. Comparative Inhibition of the GH/IGF-I Axis Obtained With Either the Targeted Secretion Inhibitor SXN101959 or the Somatostatin Analog Octreotide in Growing Male Rats. Endocrinology 2013;154:4237-48. [DOI: 10.1210/en.2013-1427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
213 Hernández B, López-tobar E, Sanchez-cortes S, Coïc Y, Baron B, Chenal A, Kruglik SG, Pflüger F, Cohen R, Ghomi M. From bulk to plasmonic nanoparticle surfaces: the behavior of two potent therapeutic peptides, octreotide and pasireotide. Phys Chem Chem Phys 2016;18:24437-50. [DOI: 10.1039/c6cp04421b] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
214 Ganetsky A, Bhatt V. Gastroenteropancreatic neuroendocrine tumors: Update on therapeutics. Ann Pharmacother. 2012;46:851-862. [PMID: 22589450 DOI: 10.1345/aph.1q729] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
215 Arregger AL, Cardoso EM, Sandoval OB, Monardes Tumilasci EG, Sanchez R, Contreras LN. Hormonal secretion and quality of life in Nelson syndrome and Cushing disease after long acting repeatable octreotide: a short series and update. Am J Ther 2014;21:e110-6. [PMID: 22820717 DOI: 10.1097/MJT.0b013e318255bc07] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
216 Atkinson H, England JA, Rafferty A, Jesudason V, Bedford K, Karsai L, Atkin SL. Somatostatin receptor expression in thyroid disease. Int J Exp Pathol 2013;94:226-9. [PMID: 23672766 DOI: 10.1111/iep.12024] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
217 Naydenova E, Wesselinova D, Staykova S, Danalev D, Dzimbova T. Synthesis, in vitro biological activity and docking of new analogs of BIM-23052 containing unnatural amino acids. Amino Acids 2019;51:1247-57. [PMID: 31350614 DOI: 10.1007/s00726-019-02758-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Liu Q, Cescato R, Dewi DA, Rivier J, Reubi J, Schonbrunn A. Receptor Signaling and Endocytosis Are Differentially Regulated by Somatostatin Analogs. Mol Pharmacol 2005;68:90-101. [DOI: 10.1124/mol.105.011767] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 4.8] [Reference Citation Analysis]
219 Van Binnebeek S, Koole M, Terwinghe C, Baete K, Vanbilloen B, Haustermans K, Clement P, Bogaerts K, Verbruggen A, Nackaerts K, Van Cutsem E, Verslype C, Mottaghy F, Deroose C. Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients: Correlation of parameters during PRRT. Nuklearmedizin 2018;55:104-14. [DOI: 10.3413/nukmed-0742-15-05] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
220 Cervia D, Casini G. The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story. Curr Neuropharmacol 2013;11:95-101. [PMID: 23814541 DOI: 10.2174/157015913804999423] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
221 Singh AT, Jaggi M, Prasad S, Dutt S, Singh G, Datta K, Rajendran P, Sanna VK, Mukherjee R, Burman AC. Modulation of key signal transduction molecules by a novel peptide combination effective for the treatment of gastrointestinal carcinomas. Invest New Drugs 2008;26:505-16. [PMID: 18322652 DOI: 10.1007/s10637-008-9119-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
222 Song KB, Kim SC, Kim JH, Seo DW, Hong SM, Park KM, Hwang DW, Lee JH, Lee YJ. Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors. Pancreas 2016;45:187-92. [PMID: 26474434 DOI: 10.1097/MPA.0000000000000493] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
223 Barragán F, López-Senín P, Salassa L, Betanzos-Lara S, Habtemariam A, Moreno V, Sadler PJ, Marchán V. Photocontrolled DNA binding of a receptor-targeted organometallic ruthenium(II) complex. J Am Chem Soc 2011;133:14098-108. [PMID: 21797210 DOI: 10.1021/ja205235m] [Cited by in Crossref: 147] [Cited by in F6Publishing: 125] [Article Influence: 14.7] [Reference Citation Analysis]
224 Enck S, Kopp F, Marahiel MA, Geyer A. The entropy balance of nostocyclopeptide macrocyclization analysed by NMR spectroscopy. Chembiochem 2008;9:2597-601. [PMID: 18821552 DOI: 10.1002/cbic.200800314] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
225 Sun X, Li Y, Liu T, Li Z, Zhang X, Chen X. Peptide-based imaging agents for cancer detection. Adv Drug Deliv Rev 2017;110-111:38-51. [PMID: 27327937 DOI: 10.1016/j.addr.2016.06.007] [Cited by in Crossref: 109] [Cited by in F6Publishing: 99] [Article Influence: 21.8] [Reference Citation Analysis]
226 Hasskarl J, Kaufmann M, Schmid HA. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future Oncology 2011;7:895-913. [DOI: 10.2217/fon.11.66] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
227 Messchendorp AL, Casteleijn NF, Meijer E, Gansevoort RT. Somatostatin in renal physiology and autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2020;35:1306-16. [PMID: 31077332 DOI: 10.1093/ndt/gfz054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
228 Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment of insomnia. Expert Rev Clin Pharmacol 2014;7:711-30. [PMID: 25318834 DOI: 10.1586/17512433.2014.966813] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
229 Hurevich M, Tal-gan Y, Klein S, Barda Y, Levitzki A, Gilon C. Novel method for the synthesis of urea backbone cyclic peptides using new Alloc-protected glycine building units: NOVEL METHOD FOR THE SYNTHESIS OF UREA BACKBONE CYCLIC PEPTIDES. J Peptide Sci 2010;16:178-85. [DOI: 10.1002/psc.1218] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
230 Xu J, Shi J, Cui X, Cui Y, Li JJ, Goel A, Chen X, Issa JP, Su J, Li W. Cellular Heterogeneity-Adjusted cLonal Methylation (CHALM) improves prediction of gene expression. Nat Commun 2021;12:400. [PMID: 33452255 DOI: 10.1038/s41467-020-20492-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
231 Dockray GJ. Gastrointestinal Hormones: Gastrin, Cholecystokinin, Somatostatin, and Ghrelin. Physiology of the Gastrointestinal Tract. Elsevier; 2006. pp. 91-120. [DOI: 10.1016/b978-012088394-3/50007-6] [Cited by in Crossref: 10] [Article Influence: 0.7] [Reference Citation Analysis]
232 Wang W, Wen Y, Xu L, Du H, Zhou Y, Zhang X. A Selective Release System Based on Dual‐Drug‐Loaded Mesoporous Silica for Nanoparticle‐Assisted Combination Therapy. Chem Eur J 2014;20:7796-802. [DOI: 10.1002/chem.201402334] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
233 Cervia D, Casini G, Bagnoli P. Physiology and pathology of somatostatin in the mammalian retina: a current view. Mol Cell Endocrinol 2008;286:112-22. [PMID: 18242820 DOI: 10.1016/j.mce.2007.12.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
234 Sato K, Francis H, Zhou T, Meng F, Kennedy L, Ekser B, Baiocchi L, Onori P, Mancinelli R, Gaudio E, Franchitto A, Glaser S, Alpini G. Neuroendocrine Changes in Cholangiocarcinoma Growth. Cells 2020;9:E436. [PMID: 32069926 DOI: 10.3390/cells9020436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
235 Erchegyi J, Cescato R, Waser B, Rivier JE, Reubi JC. N-imidazolebenzyl-histidine substitution in somatostatin and in its octapeptide analogue modulates receptor selectivity and function. J Med Chem 2011;54:5981-7. [PMID: 21806016 DOI: 10.1021/jm200307v] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
236 Ayiomamitis GD, Notas G, Zaravinos A, Drygiannakis I, Georgiadou M, Sfakianaki O, Mastrodimou N, Thermos K, Kouroumalis E. Effects of octreotide and insulin on colon cancer cellular proliferation and correlation with hTERT activity. Oncoscience 2014;1:457-67. [PMID: 25594044 DOI: 10.18632/oncoscience.58] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
237 Mothes C, Larregola M, Quancard J, Goasdoué N, Lavielle S, Chassaing G, Lequin O, Karoyan P. Prolinoamino Acids as Tools to Build Bifunctionalized, Stable β-Turns in Water. Chem Eur J of Chem Bio 2010;11:55-8. [DOI: 10.1002/cbic.200900572] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
238 Hernández B, Coïc YM, López-Tobar E, Sanchez-Cortes S, Baron B, Pflüger F, Kruglik SG, Cohen R, Ghomi M. Dynamical Behavior of Somatostatin-14 and Its Cyclic Analogues as Analyzed in Bulk and on Plasmonic Silver Nanoparticles. Adv Protein Chem Struct Biol 2018;112:81-121. [PMID: 29680244 DOI: 10.1016/bs.apcsb.2018.01.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
239 Arnaldi G, Boscaro M. Pasireotide for the treatment of Cushing's disease. Expert Opinion on Investigational Drugs 2010;19:889-98. [DOI: 10.1517/13543784.2010.495943] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
240 Msaouel P, Galanis E, Koutsilieris M. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opin Investig Drugs 2009;18:1297-316. [PMID: 19678799 DOI: 10.1517/13543780903176399] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
241 Hernández-Pinto AM, Puebla-Jiménez L, Perianes-Cachero A, Arilla-Ferreiro E. Vitamin E deficiency impairs the somatostatinergic receptor-effector system and leads to phosphotyrosine phosphatase overactivation and cell death in the rat hippocampus. J Nutr Biochem 2013;24:848-58. [PMID: 22902329 DOI: 10.1016/j.jnutbio.2012.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
242 Eberle AN, Mild G, Froidevaux S. Receptor-Mediated Tumor Targeting with Radiopeptides. Part 1. General Concepts and Methods: Applications to Somatostatin Receptor-Expressing Tumors. Journal of Receptors and Signal Transduction 2004;24:319-455. [DOI: 10.1081/rrs-200040939] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
243 Jung Y, Oh SH, Zheng D, Shupe TD, Witek RP, Petersen BE. A potential role of somatostatin and its receptor SSTR4 in the migration of hepatic oval cells. Lab Invest. 2006;86:477-489. [PMID: 16534498 DOI: 10.1038/labinvest.3700410] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
244 Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17:1733-1742. [PMID: 16801334 DOI: 10.1093/annonc/mdl105] [Cited by in Crossref: 194] [Cited by in F6Publishing: 167] [Article Influence: 12.9] [Reference Citation Analysis]
245 Reis J, Gaspar A, Milhazes N, Borges F. Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances. J Med Chem 2017;60:7941-57. [PMID: 28537720 DOI: 10.1021/acs.jmedchem.6b01720] [Cited by in Crossref: 140] [Cited by in F6Publishing: 96] [Article Influence: 35.0] [Reference Citation Analysis]
246 Engin E, Treit D. Anxiolytic and antidepressant actions of somatostatin: the role of sst2 and sst3 receptors. Psychopharmacology (Berl) 2009;206:281-9. [PMID: 19609508 DOI: 10.1007/s00213-009-1605-5] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 4.2] [Reference Citation Analysis]
247 Siehler S, Nunn C, Zupanc GK, Hoyer D. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures. Auton Autacoid Pharmacol 2005;25:1-16. [PMID: 15659149 DOI: 10.1111/j.1474-8673.2004.00325.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
248 Pratesi A, Ginanneschi M, Lumini M, Papini AM, Novellino E, Brancaccio D, Carotenuto A. DOTA-Derivatives of Octreotide Dicarba-Analogs with High Affinity for Somatostatin sst2,5 Receptors. Front Chem 2017;5:8. [PMID: 28286746 DOI: 10.3389/fchem.2017.00008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
249 Fridén-saxin M, Seifert T, Malo M, da Silva Andersson K, Pemberton N, Dyrager C, Friberg A, Dahlén K, Wallén EA, Grøtli M, Luthman K. Chroman-4-one and chromone based somatostatin β-turn mimetics. European Journal of Medicinal Chemistry 2016;114:59-64. [DOI: 10.1016/j.ejmech.2016.02.046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
250 Nagarajan SK, Babu S, Sohn H, Madhavan T. Molecular-Level Understanding of the Somatostatin Receptor 1 (SSTR1)-Ligand Binding: A Structural Biology Study Based on Computational Methods. ACS Omega 2020;5:21145-61. [PMID: 32875251 DOI: 10.1021/acsomega.0c02847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
251 Ben-Shlomo A, Melmed S. Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 2008;286:192-8. [PMID: 18191325 DOI: 10.1016/j.mce.2007.11.024] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 4.6] [Reference Citation Analysis]
252 Jaggi M, Prasad S, Singh AT, Praveen R, Dutt S, Mathur A, Sharma R, Gupta N, Ahuja R, Mukherjee R, Burman AC. Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors. Invest New Drugs 2008;26:489-504. [PMID: 18217205 DOI: 10.1007/s10637-008-9117-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
253 Ko CH, Yi S, Ozaki R, Cochrane H, Chung H, Lau W, Koon CM, Hoi SW, Lo W, Cheng KF, Lau CB, Chan WY, Leung PC, Chan JC. Healing effect of a two-herb recipe (NF3) on foot ulcers in Chinese patients with diabetes: a randomized double-blind placebo-controlled study. J Diabetes 2014;6:323-34. [PMID: 24330156 DOI: 10.1111/1753-0407.12117] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
254 Lehman JM, Hoeksema MD, Staub J, Qian J, Harris B, Callison JC, Miao J, Shi C, Eisenberg R, Chen H, Chen SC, Massion PP. Somatostatin receptor 2 signaling promotes growth and tumor survival in small-cell lung cancer. Int J Cancer 2019;144:1104-14. [PMID: 30152518 DOI: 10.1002/ijc.31771] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
255 He R, Finan B, Mayer JP, DiMarchi RD. Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety. Molecules 2019;24:E1855. [PMID: 31091786 DOI: 10.3390/molecules24101855] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 17.5] [Reference Citation Analysis]
256 Cohan P. Pasireotide and Mifepristone: New Options in the Medical Management of Cushing's Disease. Endocrine Practice 2014;20:84-93. [DOI: 10.4158/ep13127.ra] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
257 van Hagen PM, Dalm VA, Staal F, Hofland LJ. The role of cortistatin in the human immune system. Molecular and Cellular Endocrinology 2008;286:141-7. [DOI: 10.1016/j.mce.2008.03.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
258 Lin LC, Sibille E. Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target? Front Pharmacol 2013;4:110. [PMID: 24058344 DOI: 10.3389/fphar.2013.00110] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 8.1] [Reference Citation Analysis]
259 North AJ, Karas JA, Ma MT, Blower PJ, Ackermann U, White JM, Donnelly PS. Rhenium and Technetium-oxo Complexes with Thioamide Derivatives of Pyridylhydrazine Bifunctional Chelators Conjugated to the Tumour Targeting Peptides Octreotate and Cyclic-RGDfK. Inorg Chem 2017;56:9725-41. [PMID: 28766938 DOI: 10.1021/acs.inorgchem.7b01247] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
260 Borisova LM, Kiseleva MP, Osipov VN, Sushinina LP, Ustinkina SV, Smirnova LI, Shprakh ZS. Cyphetrylin cytotoxic analogues (report II). Rossijskij bioterapevtičeskij žurnal 2017;16:23-9. [DOI: 10.17650/1726-9784-2017-16-2-23-29] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
261 Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology. 2004;80 Suppl 1:47-50. [PMID: 15477717 DOI: 10.1159/000080741] [Cited by in Crossref: 116] [Cited by in F6Publishing: 104] [Article Influence: 6.8] [Reference Citation Analysis]
262 Jian K, Barhoumi R, Ko ML, Ko GY. Inhibitory effect of somatostatin-14 on L-type voltage-gated calcium channels in cultured cone photoreceptors requires intracellular calcium. J Neurophysiol 2009;102:1801-10. [PMID: 19605612 DOI: 10.1152/jn.00354.2009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
263 Simon Á, Kéri G, Kardos J. Comparison of the binding modes of TT-232 in somatostatin receptors type 1 and 4. Journal of Molecular Structure: THEOCHEM 2007;816:73-6. [DOI: 10.1016/j.theochem.2007.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
264 Smith PA. N-Type Ca2+-Channels in Murine Pancreatic β-Cells Are Inhibited by an Exclusive Coupling with Somatostatin Receptor Subtype 1. Endocrinology 2009;150:741-8. [DOI: 10.1210/en.2008-0883] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
265 Ribeiro-Oliveira A Jr, Schweizer JROL, Amaral PHS, Bizzi MF, Silveira WCD, Espirito-Santo DTA, Zille G, Soares BS, Schmid HA, Yuen KCJ. Pasireotide treatment does not modify hyperglycemic and corticosterone acute restraint stress responses in rats. Stress 2018;21:370-5. [PMID: 29661114 DOI: 10.1080/10253890.2018.1451838] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
266 Seidler C, Zegota MM, Raabe M, Kuan SL, Ng DYW, Weil T. Dynamic Core-Shell Bioconjugates for Targeted Protein Delivery and Release. Chem Asian J 2018;13:3474-9. [PMID: 30036452 DOI: 10.1002/asia.201800843] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
267 Forssell-Aronsson E, Spetz J, Ahlman H. Radionuclide therapy via SSTR: future aspects from experimental animal studies. Neuroendocrinology 2013;97:86-98. [PMID: 22572526 DOI: 10.1159/000336086] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
268 Knör S, Modlinger A, Poethko T, Schottelius M, Wester HJ, Kessler H. Synthesis of novel 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA) derivatives for chemoselective attachment to unprotected polyfunctionalized compounds. Chemistry 2007;13:6082-90. [PMID: 17503419 DOI: 10.1002/chem.200700231] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
269 Kántás B, Börzsei R, Szőke É, Bánhegyi P, Horváth Á, Hunyady Á, Borbély É, Hetényi C, Pintér E, Helyes Z. Novel Drug-Like Somatostatin Receptor 4 Agonists are Potential Analgesics for Neuropathic Pain. Int J Mol Sci 2019;20:E6245. [PMID: 31835716 DOI: 10.3390/ijms20246245] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
270 Kunos CA, Rubinstein LV, Capala J, McDonald MA. Phase 0 Radiopharmaceutical-Agent Clinical Development. Front Oncol 2020;10:1310. [PMID: 33014772 DOI: 10.3389/fonc.2020.01310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
271 Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol Metab 2010;21:123-33. [PMID: 20149677 DOI: 10.1016/j.tem.2009.12.003] [Cited by in Crossref: 134] [Cited by in F6Publishing: 111] [Article Influence: 12.2] [Reference Citation Analysis]
272 Zatelli MC. Antiproliferative effects of somatostatin analogs in endocrine tumours. F1000 Med Rep 2009;1:40. [PMID: 20948740 DOI: 10.3410/M1-40] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
273 Bocci G, Culler MD, Fioravanti A, Orlandi P, Fasciani A, Colucci R, Taylor JE, Sadat D, Danesi R, Del Tacca M. In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists. Eur J Clin Invest 2007;37:700-8. [PMID: 17696959 DOI: 10.1111/j.1365-2362.2007.01848.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
274 Seney ML, Tripp A, McCune S, Lewis DA, Sibille E. Laminar and cellular analyses of reduced somatostatin gene expression in the subgenual anterior cingulate cortex in major depression. Neurobiol Dis 2015;73:213-9. [PMID: 25315685 DOI: 10.1016/j.nbd.2014.10.005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
275 Yeung M, Treit D. The anxiolytic effects of somatostatin following intra-septal and intra-amygdalar microinfusions are reversed by the selective sst2 antagonist PRL2903. Pharmacol Biochem Behav 2012;101:88-92. [PMID: 22210489 DOI: 10.1016/j.pbb.2011.12.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
276 Colucci R, Blandizzi C, Ghisu N, Florio T, Del Tacca M. Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation. Br J Pharmacol. 2008;155:198-209. [PMID: 18587421 DOI: 10.1038/bjp.2008.268] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
277 Melmed S, Kleinberg D. Pituitary Masses and Tumors. Williams Textbook of Endocrinology. Elsevier; 2011. pp. 229-90. [DOI: 10.1016/b978-1-4377-0324-5.00009-2] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
278 Lucas SJ, Armstrong DL. Protein phosphatase modulation of somatostatin receptor signaling in the mouse hippocampus. Neuropharmacology 2015;99:232-41. [PMID: 26196943 DOI: 10.1016/j.neuropharm.2015.07.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
279 Deshmukh MV, Voll G, Kühlewein A, Mäcke H, Schmitt J, Kessler H, Gemmecker G. NMR Studies Reveal Structural Differences between the Gallium and Yttrium Complexes of DOTA- d -Phe-Tyr 3 -octreotide. J Med Chem 2005;48:1506-14. [DOI: 10.1021/jm0496335] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
280 Brom M, Joosten L, Oyen WJ, Gotthardt M, Boerman OC. Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas. Contrast Media Mol Imaging 2012;7:160-6. [PMID: 22434628 DOI: 10.1002/cmmi.475] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
281 Petersenn S, Farrall AJ, De Block C, Melmed S, Schopohl J, Caron P, Cuneo R, Kleinberg D, Colao A, Ruffin M, Hermosillo Reséndiz K, Hughes G, Hu K, Barkan A. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary 2014;17:132-40. [PMID: 23529827 DOI: 10.1007/s11102-013-0478-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
282 Kumar U, Grant M. Somatostatin and somatostatin receptors. Results Probl Cell Differ 2010;50:137-84. [PMID: 19859675 DOI: 10.1007/400_2009_29] [Cited by in Crossref: 10] [Cited by in F6Publishing: 28] [Article Influence: 0.9] [Reference Citation Analysis]
283 Lee S, Xie J, Chen X. Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev 2010;110:3087-111. [PMID: 20225899 DOI: 10.1021/cr900361p] [Cited by in Crossref: 228] [Cited by in F6Publishing: 209] [Article Influence: 20.7] [Reference Citation Analysis]
284 Brand Y, Radojevic V, Sung M, Wei E, Setz C, Glutz A, Leitmeyer K, Bodmer D. Role of somatostatin receptor-2 in gentamicin-induced auditory hair cell loss in the Mammalian inner ear. PLoS One 2014;9:e108146. [PMID: 25268135 DOI: 10.1371/journal.pone.0108146] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
285 Puig Domingo M. Treatment of acromegaly in the era of personalized and predictive medicine. Clin Endocrinol (Oxf) 2015;83:3-14. [PMID: 25640882 DOI: 10.1111/cen.12731] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
286 Hosono T, Bando M, Mizushina Y, Sata M, Hagiwara K, Sugiyama Y. Inhibitory effects of somatostatin analogue in bleomycin-induced pulmonary fibrosis. Exp Lung Res 2021;47:280-8. [PMID: 33899633 DOI: 10.1080/01902148.2021.1916650] [Reference Citation Analysis]
287 Dong SS, Abrol R, Goddard WA 3rd. The predicted ensemble of low-energy conformations of human somatostatin receptor subtype 5 and the binding of antagonists. ChemMedChem 2015;10:650-61. [PMID: 25772628 DOI: 10.1002/cmdc.201500023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
288 Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 2013;34:228-52. [PMID: 23872332 DOI: 10.1016/j.yfrne.2013.07.005] [Cited by in Crossref: 170] [Cited by in F6Publishing: 149] [Article Influence: 21.3] [Reference Citation Analysis]
289 Cervia D, Martini D, Ristori C, Catalani E, Timperio AM, Bagnoli P, Casini G. Modulation of the neuronal response to ischaemia by somatostatin analogues in wild-type and knock-out mouse retinas. J Neurochem. 2008;106:2224-2235. [PMID: 18624922 DOI: 10.1111/j.1471-4159.2008.05556.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
290 Engström M, Tomperi J, El-Darwish K, Ahman M, Savola JM, Wurster S. Superagonism at the human somatostatin receptor subtype 4. J Pharmacol Exp Ther 2005;312:332-8. [PMID: 15333679 DOI: 10.1124/jpet.104.075531] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
291 Vockel M, Pollok S, Breitenbach U, Ridderbusch I, Kreienkamp HJ, Brandner JM. Somatostatin inhibits cell migration and reduces cell counts of human keratinocytes and delays epidermal wound healing in an ex vivo wound model. PLoS One 2011;6:e19740. [PMID: 21589940 DOI: 10.1371/journal.pone.0019740] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
292 Bram Z, Xekouki P, Louiset E, Keil MF, Avgeropoulos D, Giatzakis C, Nesterova M, Sinaii N, Hofland LJ, Cherqaoui R, Lefebvre H, Stratakis CA. Does somatostatin have a role in the regulation of cortisol secretion in primary pigmented nodular adrenocortical disease (ppnad)? a clinical and in vitro investigation. J Clin Endocrinol Metab 2014;99:E891-901. [PMID: 24512486 DOI: 10.1210/jc.2013-2657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
293 Avdeev DV, Sidorova MV, Ovchinnikov MV, Moiseeva NI, Osipov VN, Balaev AN, Khachatryan DS. Synthesis and Antitumor Activity of Conjugates Based on the Phe-D-Trp-Lys-Thr Peptide Fragment of Somatostatin. Russ J Bioorg Chem 2019;45:248-52. [DOI: 10.1134/s1068162019040034] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
294 Gougeon A, Delangle A, Arouche N, Stridsberg M, Gotteland JP, Loumaye E. Kit Ligand and the Somatostatin Receptor Antagonist, BIM-23627, Stimulate in Vitro Resting Follicle Growth in the Neonatal Mouse Ovary. Endocrinology 2010;151:1299-309. [DOI: 10.1210/en.2009-0762] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
295 Sampedro-Núñez M, Luque RM, Ramos-Levi AM, Gahete MD, Serrano-Somavilla A, Villa-Osaba A, Adrados M, Ibáñez-Costa A, Martín-Pérez E, Culler MD, Marazuela M, Castaño JP. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. Oncotarget 2016;7:6593-608. [PMID: 26673010 DOI: 10.18632/oncotarget.6565] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
296 Albertelli M, Arvigo M, Boschetti M, Ferone D, Gatto F, Minuto F. Somatostatin receptor pathophysiology in the neuroendocrine system. Expert Rev Endocrinol Metab 2013;8:149-57. [PMID: 30736175 DOI: 10.1586/eem.13.7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
297 Armani C, Catalani E, Balbarini A, Bagnoli P, Cervia D. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J Leukoc Biol. 2007;81:845-855. [PMID: 17148691 DOI: 10.1189/jlb.0606417] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 5.5] [Reference Citation Analysis]
298 War SA, Somvanshi RK, Kumar U. Somatostatin receptor-3 mediated intracellular signaling and apoptosis is regulated by its cytoplasmic terminal. Biochim Biophys Acta 2011;1813:390-402. [PMID: 21194548 DOI: 10.1016/j.bbamcr.2010.12.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
299 Amartey J, Esguerra C, Al-jammaz I, Parhar R, Al-otaibi B. Synthesis and evaluation of radioiodinated substituted -naphthylalanine as a potential probe for pancreatic -cells imaging. Applied Radiation and Isotopes 2006;64:769-77. [DOI: 10.1016/j.apradiso.2006.01.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
300 War SA, Kumar U. Coexpression of human somatostatin receptor-2 (SSTR2) and SSTR3 modulates antiproliferative signaling and apoptosis. J Mol Signal 2012;7:5. [PMID: 22651821 DOI: 10.1186/1750-2187-7-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
301 Petrel C, Hocking HG, Reynaud M, Upert G, Favreau P, Biass D, Paolini-Bertrand M, Peigneur S, Tytgat J, Gilles N, Hartley O, Boelens R, Stocklin R, Servent D. Identification, structural and pharmacological characterization of τ-CnVA, a conopeptide that selectively interacts with somatostatin sst3 receptor. Biochem Pharmacol 2013;85:1663-71. [PMID: 23567999 DOI: 10.1016/j.bcp.2013.03.019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
302 Chen K, Conti PS. Target-specific delivery of peptide-based probes for PET imaging. Advanced Drug Delivery Reviews 2010;62:1005-22. [DOI: 10.1016/j.addr.2010.09.004] [Cited by in Crossref: 116] [Cited by in F6Publishing: 102] [Article Influence: 10.5] [Reference Citation Analysis]
303 Anderson P, Delgado M. Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders. J Cell Mol Med 2008;12:1830-47. [PMID: 18554314 DOI: 10.1111/j.1582-4934.2008.00387.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
304 Grondelle WV, Iglesias CL, Coll E, Artzner F, Paternostre M, Lacombe F, Cardus M, Martinez G, Montes M, Cherif-cheikh R, Valéry C. Spontaneous fibrillation of the native neuropeptide hormone Somatostatin-14. Journal of Structural Biology 2007;160:211-23. [DOI: 10.1016/j.jsb.2007.08.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
305 Saito F, Bode JW. Synthesis and stabilities of peptide-based [1]rotaxanes: molecular grafting onto lasso peptide scaffolds. Chem Sci 2017;8:2878-84. [PMID: 28553526 DOI: 10.1039/c7sc00021a] [Cited by in Crossref: 29] [Cited by in F6Publishing: 4] [Article Influence: 7.3] [Reference Citation Analysis]
306 Siehler S, Nunn C, Hannon J, Feuerbach D, Hoyer D. Pharmacological profile of somatostatin and cortistatin receptors. Molecular and Cellular Endocrinology 2008;286:26-34. [DOI: 10.1016/j.mce.2007.12.007] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 4.0] [Reference Citation Analysis]
307 Gastambide F, Viollet C, Lepousez G, Epelbaum J, Guillou JL. Hippocampal SSTR4 somatostatin receptors control the selection of memory strategies. Psychopharmacology (Berl) 2009;202:153-63. [PMID: 18521573 DOI: 10.1007/s00213-008-1204-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
308 Wolkenberg SE, Zhao Z, Thut C, Maxwell JW, Mcdonald TP, Kinose F, Reilly M, Lindsley CW, Hartman GD. Design, Synthesis, and Evaluation of Novel 3,6-Diaryl-4-aminoalkoxyquinolines as Selective Agonists of Somatostatin Receptor Subtype 2. J Med Chem 2011;54:2351-8. [DOI: 10.1021/jm101501b] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
309 Ishida A, Tajima Y, Okabe Y, Matsushita T, Sekiguchi T, Imaide S, Nomura Y, Tanaka M, Nojima S, Yoshida A, Iyoda Y, Aoki S, Nishio T, Komagata T, Iwaki M, Shono T, Naganawa A, Imagawa A. Discovery and SAR Studies of Orally Active Somatostatin Receptor Subtype-2 (SSTR2) Agonists for the Treatment of Acromegaly. ACS Chem Neurosci 2020;11:1482-94. [DOI: 10.1021/acschemneuro.0c00124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
310 Beierle JM, Horne WS, van Maarseveen JH, Waser B, Reubi JC, Ghadiri MR. Conformationally homogeneous heterocyclic pseudotetrapeptides as three-dimensional scaffolds for rational drug design: receptor-selective somatostatin analogues. Angew Chem Int Ed Engl 2009;48:4725-9. [PMID: 19266506 DOI: 10.1002/anie.200805901] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 6.8] [Reference Citation Analysis]
311 Lee S, Xie J, Chen X. Peptide-based probes for targeted molecular imaging. Biochemistry 2010;49:1364-76. [PMID: 20102226 DOI: 10.1021/bi901135x] [Cited by in Crossref: 210] [Cited by in F6Publishing: 190] [Article Influence: 19.1] [Reference Citation Analysis]
312 Cervia D, Bagnoli P. An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology. Pharmacol Ther 2007;116:322-41. [PMID: 17719647 DOI: 10.1016/j.pharmthera.2007.06.010] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
313 Strosberg JR. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options. Endocr Pract. 2014;20:167-175. [PMID: 24014009 DOI: 10.4158/ep13262.ra] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
314 Ertilav M, Hur E, Bozkurt D, Sipahi S, Timur O, Sarsik B, Akcicek F, Duman S. Octreotide lessens peritoneal injury in experimental encapsulated peritoneal sclerosis model: Octreotide treatment in EPS. Nephrology 2011;16:552-7. [DOI: 10.1111/j.1440-1797.2011.01460.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
315 Sukopp M, Schwab R, Marinelli L, Biron E, Heller M, Várkondi E, Pap Á, Novellino E, Kéri G, Kessler H. Structure−Activity Relationship Studies Optimizing the Antiproliferative Activity of Novel Cyclic Somatostatin Analogues Containing a Restrained Cyclic β-Amino Acid. J Med Chem 2005;48:2916-26. [DOI: 10.1021/jm049500j] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
316 Kim JK, Kwon O, Kim J, Kim EK, Park HK, Lee JE, Kim KL, Choi JW, Lim S, Seok H, Lee-Kwon W, Choi JH, Kang BH, Kim S, Ryu SH, Suh PG. PDZ domain-containing 1 (PDZK1) protein regulates phospholipase C-β3 (PLC-β3)-specific activation of somatostatin by forming a ternary complex with PLC-β3 and somatostatin receptors. J Biol Chem 2012;287:21012-24. [PMID: 22528496 DOI: 10.1074/jbc.M111.337865] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
317 Petrich A, Mann A, Kliewer A, Nagel F, Strigli A, Märtens JC, Pöll F, Schulz S. Phosphorylation of threonine 333 regulates trafficking of the human sst5 somatostatin receptor. Mol Endocrinol 2013;27:671-82. [PMID: 23418396 DOI: 10.1210/me.2012-1329] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
318 Wang X, Fani M, Schulz S, Rivier J, Reubi JC, Maecke HR. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. Eur J Nucl Med Mol Imaging 2012;39:1876-85. [DOI: 10.1007/s00259-012-2231-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
319 Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, Giacomi N, O’Connor J, Méndez G, Roca E. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis. 2010;42:220-225. [PMID: 19819769 DOI: 10.1016/j.dld.2009.07.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
320 Alonso-Gordoa T, Capdevila J, Grande E. GEP-NETs update: Biotherapy for neuroendocrine tumours. Eur J Endocrinol. 2015;172:R31-R46. [PMID: 25430657 DOI: 10.1530/eje-14-0354] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
321 Li D, Wu Z, Yu Y, Ball RG, Guo L, Sherer E, He S, Hong Q, Lai Z, Qi H, Truong Q, Yang DX, Chicchi GG, Tsao KL, Trusca D, Trujillo M, Pachanski M, Eiermann GJ, Howard AD, Zhou YP, Zhang BB, Nargund RP, Hagmann WK. Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor Agonists. ACS Med Chem Lett 2014;5:690-5. [PMID: 24944745 DOI: 10.1021/ml500079u] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
322 Strosberg JR, Cheema A, Kvols LK. A Review of Systemic and Liver-Directed Therapies for Metastatic Neuroendocrine Tumors of the Gastroenteropancreatic Tract. Cancer Control 2011;18:127-37. [DOI: 10.1177/107327481101800207] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
323 Mei S, Cammalleri M, Azara D, Casini G, Bagnoli P, Dal Monte M. Mechanisms underlying somatostatin receptor 2 down-regulation of vascular endothelial growth factor expression in response to hypoxia in mouse retinal explants. J Pathol 2012;226:519-33. [DOI: 10.1002/path.3006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
324 Troxler T, Hurth K, Schuh K, Schoeffter P, Langenegger D, Enz A, Hoyer D. Decahydroisoquinoline derivatives as novel non-peptidic, potent and subtype-selective somatostatin sst3 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2010;20:1728-34. [DOI: 10.1016/j.bmcl.2010.01.063] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
325 Berardi R, Morgese F, Torniai M, Savini A, Partelli S, Rinaldi S, Caramanti M, Ferrini C, Falconi M, Cascinu S. Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. World J Gastrointest Oncol 2016; 8(4): 389-401 [PMID: 27096034 DOI: 10.4251/wjgo.v8.i4.389] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
326 Hernández B, Coïc YM, Kruglik SG, Carelli C, Cohen R, Ghomi M. Octreotide used for probing the type-II' β-turn CD and Raman markers. J Phys Chem B 2012;116:9337-45. [PMID: 22793173 DOI: 10.1021/jp3036428] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
327 Kirzinger L, Boy S, Marienhagen J, Schuierer G, Neu R, Ried M, Hofmann HS, Wiebe K, Ströbel P, May C, Kleylein-Sohn J, Baierlein C, Bogdahn U, Marx A, Schalke B. Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. PLoS One 2016;11:e0168215. [PMID: 27992479 DOI: 10.1371/journal.pone.0168215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
328 Gonzalez-rey E, Delgado M. Emergence of cortistatin as a new immunomodulatory factor with therapeutic potential in immune disorders. Molecular and Cellular Endocrinology 2008;286:135-40. [DOI: 10.1016/j.mce.2007.08.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
329 Dunning BE, Gerich JE. The Role of α-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications. Endocrine Reviews 2007;28:253-83. [DOI: 10.1210/er.2006-0026] [Cited by in Crossref: 252] [Cited by in F6Publishing: 232] [Article Influence: 18.0] [Reference Citation Analysis]
330 Barbieri F, Pattarozzi A, Gatti M, Aiello C, Quintero A, Lunardi G, Bajetto A, Ferrari A, Culler MD, Florio T. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am J Physiol Endocrinol Metab 2009;297:E1078-88. [PMID: 19706788 DOI: 10.1152/ajpendo.00292.2009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
331 Neelamkavil S, Arison B, Birzin E, Feng JJ, Chen KH, Lin A, Cheng FC, Taylor L, Thornton ER, Smith AB 3rd, Hirschmann R. Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSST2 and hSST4. An unexpected effect of the chirality of Trp8 on NMR spectra in methanol. J Med Chem 2005;48:4025-30. [PMID: 15943475 DOI: 10.1021/jm058184l] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
332 Ristori C, Cammalleri M, Martini D, Pavan B, Casini G, Cervia D, Bagnoli P. The cyclooxygenase-2/prostaglandin E2 pathway is involved in the somatostatin-induced decrease of epileptiform bursting in the mouse hippocampus. Neuropharmacology 2008;54:874-84. [DOI: 10.1016/j.neuropharm.2008.01.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
333 Carmichael JD, Bonert VS, Nuño M, Ly D, Melmed S. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab 2014;99:1825-33. [PMID: 24606084 DOI: 10.1210/jc.2013-3757] [Cited by in Crossref: 88] [Cited by in F6Publishing: 75] [Article Influence: 12.6] [Reference Citation Analysis]
334 Deroose CM, Hindié E, Kebebew E, Goichot B, Pacak K, Taïeb D, Imperiale A. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. J Nucl Med 2016;57:1949-56. [PMID: 27811124 DOI: 10.2967/jnumed.116.179234] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 15.0] [Reference Citation Analysis]
335 Sreenivasan VK, Stremovskiy OA, Kelf TA, Heblinski M, Goodchild AK, Connor M, Deyev SM, Zvyagin AV. Pharmacological characterization of a recombinant, fluorescent somatostatin receptor agonist. Bioconjug Chem 2011;22:1768-75. [PMID: 21823634 DOI: 10.1021/bc200104u] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
336 Cives M, Strosberg J. The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors. Drugs 2015;75:847-58. [DOI: 10.1007/s40265-015-0397-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
337 Schulz S, Lehmann A, Kliewer A, Nagel F. Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5. Br J Pharmacol 2014;171:1591-9. [PMID: 24328848 DOI: 10.1111/bph.12551] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
338 Di Cianni A, Carotenuto A, Brancaccio D, Novellino E, Reubi JC, Beetschen K, Papini AM, Ginanneschi M. Novel Octreotide Dicarba-analogues with High Affinity and Different Selectivity for Somatostatin Receptors. J Med Chem 2010;53:6188-97. [DOI: 10.1021/jm1005868] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
339 Csaba Z, Vitalis T, Charriaut-Marlangue C, Margaill I, Coqueran B, Leger PL, Parente I, Jacquens A, Titomanlio L, Constans C, Demene C, Santin MD, Lehericy S, Perrière N, Glacial F, Auvin S, Tanter M, Ghersi-Egea JF, Adle-Biassette H, Aubry JF, Gressens P, Dournaud P. A simple novel approach for detecting blood-brain barrier permeability using GPCR internalization. Neuropathol Appl Neurobiol 2021;47:297-315. [PMID: 32898926 DOI: 10.1111/nan.12665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
340 Jallad RS, Bronstein MD. The place of medical treatment of acromegaly: current status and perspectives. Expert Opin Pharmacother 2013;14:1001-15. [PMID: 23600991 DOI: 10.1517/14656566.2013.784744] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
341 Park TSW, Khan N, Kuo A, Nicholson JR, Corradini L, Smith MT. J-2156, a somatostatin receptor type 4 agonist, alleviates mechanical hyperalgesia in a rat model of chronic low back pain. Biomed Pharmacother 2019;117:109056. [PMID: 31181441 DOI: 10.1016/j.biopha.2019.109056] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
342 Al-Nahhas A. Nuclear medicine imaging of neuroendocrine tumours. Clin Med (Lond) 2012;12:377-80. [PMID: 22930887 DOI: 10.7861/clinmedicine.12-4-377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
343 Peng J, Qi X, Chen Y, Ma N, Zhang Z, Xing J, Zhu X, Li Z, Wu Z. Octreotide-conjugated PAMAM for targeted delivery to somatostatin receptors over-expressed tumor cells. Journal of Drug Targeting 2014;22:428-38. [DOI: 10.3109/1061186x.2013.879386] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
344 Sullivan I, Le Teuff G, Guigay J, Caramella C, Berdelou A, Leboulleux S, Déandréis D, Hadoux J, Ducreux M, Duvillard P, Adam J, Scoazec J, Baudin E, Planchard D. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. European Journal of Cancer 2017;75:259-67. [DOI: 10.1016/j.ejca.2016.11.034] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
345 Jung Y, Oh SH, Witek RP, Petersen BE. Somatostatin stimulates the migration of hepatic oval cells in the injured rat liver. Liver Int 2012;32:312-20. [PMID: 22098068 DOI: 10.1111/j.1478-3231.2011.02642.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]